Archive for October, 2019

Louisiana-based Ochsner Health System is partnering with Color to launch a population health pilot program, tyinggenetic information into preventive care.

Calling it the first "fully-digital population health program," Ochsner will work with the health technology company to incorporateclinical genomics into primarycare with a focuson impacting patients' health further downstream.

Developed by Ochsners innovation lab, innovationOchsner (iO), the health systems program willidentify patients who are at higher risk for certain hereditary cancers and heart disease so these diseases can be detected early or prevented.

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

This marks another big partnership for Color this year. The company inked a similar collaboration with Chicago-based NorthShore University HealthSystem, called DNA10K, that will provide more than10,000 NorthShore patients access to Colors clinical-grade genetic testing and whole genome sequencing.Atthe time, it was touted as the largest primary care genomics program in the U.S.

RELATED:Mount Sinai to launch $100M center dedicated to AI, precision medicine

Physician practices are beginning to incorporate genomics into primary care as well.Murfreesboro Medical Clinic and SurgiCenter in Tennessee are working with technology company2bPrecise, a subsidiary of health IT company Allscripts, to integrate pharmacogenomic testresults at the point of care.

In August, Color was awarded a $4.6 million grant by the National Institutes of Health to serve as the nationwide genetic counseling service for its All of Us Research Program.

With this pilot program, Ochsner is focused on screening patients with genetic mutations that put them at increased risk for three conditionshereditary breast and ovarian cancer syndrome due to genetic mutations in the BRCA1 and BRCA2 genes; Lynch syndrome,associated with increased risk in colorectal, endometrial, ovarian and other cancers; and familial hypercholesterolemia (FH), which increases the risk for heart disease or stroke.

The Centers for Disease Control and Prevention reports thatnearly 2 million people in the U.S. are at increased risk for adverse health outcomes because they have genetic mutations with one of thosethree conditions.

Genetic screening can make a meaningful difference to patients through early detection and screening. Most consumers have access to home genetic screening tests but may not have the tools, resources, and collaboration needed to take action should they receive questionable results, said Richard Milani, M.D., chief clinical transformation officer for the Ochsner Health System and medical director for iO.

RELATED:How a Nashville-area clinic teamed up with Allscripts on precision medicine

Ochsner provides patient care across40 owned, managed and affiliated hospitals and specialty hospitals and more than 100 health centers and urgent care centers.The partnership will combine Colors capabilities inmedical-grade genetics, clinical services and patient engagement and the health system's experience withpersonalized medicineand integrating it into routine patient care, the organizations said in a press release.

As part of the program, selected patients will be enrolled into the program digitally and will receive access to genetic testing and counseling.Genetic testing results will bestored in the patients Epic electronic health record so patients and providers have access to the genetic information.

RELATED:UCLA Health deploys Microsoft Azure to accelerate medical research, precision medicine at the point of care

Ochsner also has developed clinical decision support tools and a robust provider education program for both primary care and specialty providers to integrate into clinical practice.

New technology tools like clinical genomics will enableOchsner physicians to better understand individualized risk among its patient population and create action plans that can detect or prevent disease, according to the health system.

We know there are many factors that influence health, and genetic insights provide an additional data point to allow us to develop and deliver a more personalized approach in partnership with our patients," Milani said.

"Integrating this information into the patients electronic health record so doctors can review the results and discuss proactive treatment recommendations is yet another example of how we are reengineering care, informing smarter decisions by healthcare providers and empowering patients to become more involved in their health," he said.

Read more:
Ochsner Health System teaming up with Color on population health pilot - FierceHealthcare

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.

"We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis. "Our ability to use the lymph node as a bioreactor for organogenesis is also generating interest from partner companies looking for an enabling technology so that their genetically modified cell therapies are able to engraft, proliferate, vascularize, and produce a therapeutic effect in patients."

"We are thrilled to continue our financial support of LyGenesis as they transition into clinical development," said Greg Bailey, MD, Co-Founder and CEO of Juvenescence, and a member of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvenescence.ltd.

About Longevity Vision FundLongevity Vision Fundis a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.

Media Contact:Michael Hufford, PhD+1.858.603.2514226496@email4pr.com

SOURCE LyGenesis, Inc.

http://www.lygenesis.com

Excerpt from:
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology - PRNewswire

RALEIGH, N.C., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Power Analytics, a Global corporation, and its majority shareholder Wavetech Global, Inc (the "Company" or "Power"), a global next generation technology platform company that specializes in critical system monitoring, prediction, simulation and data-analytics announced today a significant expansion of its global patent portfolio, with the granting of a new patent, demonstrating its ongoing commitment to innovation and leadership in the emerging global digital twin software industry. In addition, Power Analytics is excited to announce a new release of the Companys leading analytical software DesignBase 6.2, the core of the Companys real time microgrid and data-center product offerings including the Power Digital Twin. This release expands key areas of innovation in energy storage, time-series and dynamic analytical capability along with asset management and asset optimization.

The companys U.S. and international patent portfolio now totals 25 issued patents, with a new patent expanding coverage of real-time microgrid power management systems (SYSTEMS AND METHODS FOR REAL-TIME DC MICROGRID POWER ANALYTICS FOR MISSION-CRITICAL POWER SYSTEMS). Power Analytics patents include sophisticated real-time modeling and simulations technology, architecture, engineering and applied sciences to help its customers and partners protect their network infrastructure by preventing network downtime and allowing them to run their operations more efficiently.

From the beginning, we recognized the importance of developing and then protecting our technology, said Kevin Meagher, Power Analytics President. As a pioneer in the Power Digital Twin software, we know via our priority data capture and modeling software that we were and are ahead of the power simulation ecosystem. To have our creativity recognized by patent offices around the globe (United States, Canada, Europe, Japan, Australia and others) is a source of pride for the entire Power Analytics team and should be very comforting to our Customers, Partners and Investors.

Power Analytics leverages over 30,000 different libraries (grid element library) of devices and collecting in real-time while analyzing and running a predictive simulation of each device to improve operational efficiency rates and eliminate downtime cost impacts. The Company continues to innovate to meet the challenges that customers have in navigating the complex and dynamic network infrastructure management ecosystem. With more than 25 patent applications, Power Analytics Network Gatewayplatforms address the current marketplace requirements and Future Proof Customers ongoing infrastructure management needs.

Our proprietary technology enables us to monitor, model, predict and protect in real-time millions of Power and Network Identification Components (PICs & NICs), and give distinct insight into how to improve efficiency and improve reliability. Our platform and models can consume and process hundreds of thousands of datapoints per second and do so for some of the most important networks in the world. Our goal is to use maintain our innovation lead further invention that make power, internet and mobile network infrastructure more reliable, cost efficient and secure., stated Michael Kotlarz, Power Analytics is always looking forward to what is coming next and is furiously innovating for the challenges our Customers are facing today and likely will face in the future. Seeing patent authorities worldwide continue to point to Power Analytics pioneering technology as unique and applicable innovations is very rewarding.

Keith Barksdale of Power Analytics Global and BV Advisory Partners stated, We are excited to expand our IP portfolio and the release of a newer version of our Digital Twin software. In the coming months we will accelerate the launch of more of our proprietary AI based software product offerings that will help our customers and partners realize greater cost savings, increased revenue opportunities, and better operational efficiencies from their critical network infrastructure.

About Power Analytics GlobalPower Analytics Global is a global next generation energy management company that specializes in asset lifecycle extension, intellectual property development, and real-time analytics and asset management for power and industries supported by power. The Company offers a global portfolio of end-to-end energy optimization and lifecycle management solutions developed from proprietary intellectual property, engineered systems, and operational expertise. Power Analytics extensive suite of products include power asset life extension, operational servicing and automation, lifetime cost reduction, and real-time heterogeneous power source switching. Additional information regarding Power Analytics may be found on Power Analytics website athttp://www.poweranalytics.com

Story continues

Forward-Looking Statements:The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, including statements related to expected market trends and the Company's performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.

InvestorRelationsDamon CameronPower Analytics Global201.280.9850dcameron@poweranalytics.com

More:
Power Analytics Expands Global Patent Portfolio and the new release of software version 6.2 for DesignBase - Yahoo Finance

The report titled Antioxidant Supplement Market has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts.

Get a sample copy before purchase:

https://www.marketinsightsreports.com/reports/10171510141/global-antioxidant-supplement-market-professional-survey-report-2019/inquiry?Mode=74

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Antioxidant Supplement Market: NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension and other

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Global Antioxidant Supplement Market Split By Product Type And Applications:

This report segments the global Antioxidant Supplement Market on the basis ofTypesare:

Medical GradeFood Grade

On the basis ofApplication, the Global Antioxidant Supplement Market is segmented into:

MedicalFoodCosmetics

Regional Analysis for Antioxidant Supplement Market:

For comprehensive understanding of market dynamics, the global Antioxidant Supplement Market is analyzed across key geographies namely: United States, China, Europe, Japan, Middle East & Africa, India, and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

-Comprehensive assessment of all opportunities and risk in the Antioxidant Supplement Market.

Antioxidant Supplement Market recent innovations and major events.

-Detailed study of business strategies for growth of the Antioxidant Supplement Market -leading players.

-Conclusive study about the growth plot of Antioxidant Supplement Market for forthcoming years.

-In-depth understanding of Antioxidant Supplement Market -particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Antioxidant Supplement Market.

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/10171510141/global-antioxidant-supplement-market-professional-survey-report-2019?mode=74

Finally, Antioxidant Supplement Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please connect with our sales team (sales@marketinsightsreports.com)

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Original post:
Antioxidant Supplement Market Comprehensive Insights and Forecast 2019 to 2025 - Galus Australis

Questionable nutritional advice is easily amplified in our digital world, but older generations have always passed down health adages that younger generations found difficult to believe. Did your parents ever encourage you to drink fish oil to boost brain power before an exam, or offer mustard when you had a muscle cramp? My folks believed ginger relieves nausea. I was curious whether these adages and folk remedies could withstand the scrutiny of science or whether theyre bunkum. So I set out to research a few of them.

An apple a day keeps the doctor away

This well-known statement is based on an 1860s Welsh proverb that eating apples will diminish doctor visits. And it has actually been put to the test in a 2015 April FoolsDay issue of JAMA Internal Medicine (while the topics were zany, the studies were real).

From 15p 0.18 $0.18 USD 0.27 a day, more exclusives, analysis and extras.

Researchers investigated whether people who reported eating apples daily actually had fewer annual doctor visits or were in better overall health. Of the 8,399 study participants, 753 ate at least one small apple daily. The results showed that 39 per cent of apple eaters avoided physician visits compared to 34 per cent of non-apple eaters, which was not a statistically significant difference. Researchers did find that apple eaters were a bit less likely to require prescription medications compared to non-apple eaters, leading the researcher to joke that an apple a day keeps the pharmacist away.

Jackdaws can identify dangerous humans from listening to each others warning calls, scientists say. The highly social birds will also remember that person if they come near their nests again, according to researchers from the University of Exeter. In the study, a person unknown to the wild jackdaws approached their nest. At the same time scientists played a recording of a warning call (threatening) or contact calls (non-threatening). The next time jackdaws saw this same person, the birds that had previously heard the warning call were defensive and returned to their nests more than twice as quickly on average.

Getty

The sex of the turtle is determined by the temperatures at which they are incubated. Warm temperatures favour females.But by wiggling around the egg, embryos can find the Goldilocks Zone which means they are able to shield themselves against extreme thermal conditions and produce a balanced sex ratio, according to the new study published in Current Biology journal

Ye et al/Current Biology

African elephant poaching rates have dropped by 60 per cent in six years, an international study has found. It is thought the decline could be associated with the ivory trade ban introduced in China in 2017.

Reuters

Scientists have identified a four-legged creature with webbed feet to be an ancestor of the whale. Fossils unearthed in Peru have led scientists to conclude that the enormous creatures that traverse the planets oceans today are descended from small hoofed ancestors that lived in south Asia 50 million years ago

A. Gennari

A scientist has stumbled upon a creature with a transient anus that appears only when it is needed, before vanishing completely. Dr Sidney Tamm of the Marine Biological Laboratory could not initially find any trace of an anus on the species. However, as the animal gets full, a pore opens up to dispose of waste

Steven G Johnson

Feared extinct, the Wallace's Giant bee has been spotted for the first time in nearly 40 years. An international team of conservationists spotted the bee, that is four times the size of a typical honeybee, on an expedition to a group of Indonesian Islands

Clay Bolt

Fossilised bones digested by crocodiles have revealed the existence of three new mammal species that roamed the Cayman Islands 300 years ago. The bones belonged to two large rodent species and a small shrew-like animal

New Mexico Museum of Natural History

Scientists at the University of Maryland have created a fabric that adapts to heat, expanding to allow more heat to escape the body when warm and compacting to retain more heat when cold

Faye Levine, University of Maryland

A study from the University of Tokyo has found that the tears of baby mice cause female mice to be less interested in the sexual advances of males

Getty

The Intergovernmental Panel on Climate Change has issued a report which projects the impact of a rise in global temperatures of 1.5 degrees Celsius and warns against a higher increase

Getty

The nobel prize for chemistry has been awarded to three chemists working with evolution. Frances Smith is being awarded the prize for her work on directing the evolution of enzymes, while Gregory Winter and George Smith take the prize for their work on phage display of peptides and antibodies

Getty/AFP

The nobel prize for physics has been awarded to three physicists working with lasers. Arthur Ashkin (L) was awarded for his "optical tweezers" which use lasers to grab particles, atoms, viruses and other living cells. Donna Strickland and Grard Mourou were jointly awarded the prize for developing chirped-pulse amplification of lasers

Reuters/AP

The Ledumahadi Mafube roamed around 200 million years ago in what is now South Africa. Recently discovered by a team of international scientists, it was the largest land animal of its time, weighing 12 tons and standing at 13 feet. In Sesotho, the South African language of the region in which the dinosaur was discovered, its name means "a giant thunderclap at dawn"

Viktor Radermacher / SWNS

Scientists have witnessed the birth of a planet for the first time ever. This spectacular image from the SPHERE instrument on ESO's Very Large Telescope is the first clear image of a planet caught in the very act of formation around the dwarf star PDS 70. The planet stands clearly out, visible as a bright point to the right of the center of the image, which is blacked out by the coronagraph mask used to block the blinding light of the central star.

ESO/A. Mller et al

Layers long thought to be dense, connective tissue are actually a series of fluid-filled compartments researchers have termed the interstitium. These compartments are found beneath the skin, as well as lining the gut, lungs, blood vessels and muscles, and join together to form a network supported by a mesh of strong, flexible proteins

Getty

Working in the Brazilian state of Mato Grosso, a team led by archaeologists at the University of Exeter unearthed hundreds of villages hidden in the depths of the rainforest. These excavations included evidence of fortifications and mysterious earthworks called geoglyphs

Jos Iriarte

More than one in 10 people were found to have traces of class A drugs on their fingers by scientists developing a new fingerprint-based drug test.Using sensitive analysis of the chemical composition of sweat, researchers were able to tell the difference between those who had been directly exposed to heroin and cocaine, and those who had encountered it indirectly.

Getty

The storm bigger than the Earth, has been swhirling for 350 years. The image's colours have been enhanced after it was sent back to Earth.

Pictures by: Tom Momary

Included in Wellcome Image Awards, this 3D image of an African grey parrot shows the highly intricate system of blood vessels.

Scott Birch. Wellcome Images

Another Wellcome Images Award winner, this time of baby Hawaiian bobtail squid. The black ink sac and light organ in the centre of the squids mantle cavity can be clearly seen.

Macroscopic Solutions. Wellcome Images

Jackdaws can identify dangerous humans from listening to each others warning calls, scientists say. The highly social birds will also remember that person if they come near their nests again, according to researchers from the University of Exeter. In the study, a person unknown to the wild jackdaws approached their nest. At the same time scientists played a recording of a warning call (threatening) or contact calls (non-threatening). The next time jackdaws saw this same person, the birds that had previously heard the warning call were defensive and returned to their nests more than twice as quickly on average.

Getty

The sex of the turtle is determined by the temperatures at which they are incubated. Warm temperatures favour females.But by wiggling around the egg, embryos can find the Goldilocks Zone which means they are able to shield themselves against extreme thermal conditions and produce a balanced sex ratio, according to the new study published in Current Biology journal

Ye et al/Current Biology

African elephant poaching rates have dropped by 60 per cent in six years, an international study has found. It is thought the decline could be associated with the ivory trade ban introduced in China in 2017.

Reuters

Scientists have identified a four-legged creature with webbed feet to be an ancestor of the whale. Fossils unearthed in Peru have led scientists to conclude that the enormous creatures that traverse the planets oceans today are descended from small hoofed ancestors that lived in south Asia 50 million years ago

A. Gennari

A scientist has stumbled upon a creature with a transient anus that appears only when it is needed, before vanishing completely. Dr Sidney Tamm of the Marine Biological Laboratory could not initially find any trace of an anus on the species. However, as the animal gets full, a pore opens up to dispose of waste

Steven G Johnson

Feared extinct, the Wallace's Giant bee has been spotted for the first time in nearly 40 years. An international team of conservationists spotted the bee, that is four times the size of a typical honeybee, on an expedition to a group of Indonesian Islands

Clay Bolt

Fossilised bones digested by crocodiles have revealed the existence of three new mammal species that roamed the Cayman Islands 300 years ago. The bones belonged to two large rodent species and a small shrew-like animal

New Mexico Museum of Natural History

Scientists at the University of Maryland have created a fabric that adapts to heat, expanding to allow more heat to escape the body when warm and compacting to retain more heat when cold

Faye Levine, University of Maryland

A study from the University of Tokyo has found that the tears of baby mice cause female mice to be less interested in the sexual advances of males

Getty

The Intergovernmental Panel on Climate Change has issued a report which projects the impact of a rise in global temperatures of 1.5 degrees Celsius and warns against a higher increase

Getty

The nobel prize for chemistry has been awarded to three chemists working with evolution. Frances Smith is being awarded the prize for her work on directing the evolution of enzymes, while Gregory Winter and George Smith take the prize for their work on phage display of peptides and antibodies

Getty/AFP

The nobel prize for physics has been awarded to three physicists working with lasers. Arthur Ashkin (L) was awarded for his "optical tweezers" which use lasers to grab particles, atoms, viruses and other living cells. Donna Strickland and Grard Mourou were jointly awarded the prize for developing chirped-pulse amplification of lasers

Reuters/AP

The Ledumahadi Mafube roamed around 200 million years ago in what is now South Africa. Recently discovered by a team of international scientists, it was the largest land animal of its time, weighing 12 tons and standing at 13 feet. In Sesotho, the South African language of the region in which the dinosaur was discovered, its name means "a giant thunderclap at dawn"

Viktor Radermacher / SWNS

Scientists have witnessed the birth of a planet for the first time ever. This spectacular image from the SPHERE instrument on ESO's Very Large Telescope is the first clear image of a planet caught in the very act of formation around the dwarf star PDS 70. The planet stands clearly out, visible as a bright point to the right of the center of the image, which is blacked out by the coronagraph mask used to block the blinding light of the central star.

ESO/A. Mller et al

Layers long thought to be dense, connective tissue are actually a series of fluid-filled compartments researchers have termed the interstitium. These compartments are found beneath the skin, as well as lining the gut, lungs, blood vessels and muscles, and join together to form a network supported by a mesh of strong, flexible proteins

Getty

Working in the Brazilian state of Mato Grosso, a team led by archaeologists at the University of Exeter unearthed hundreds of villages hidden in the depths of the rainforest. These excavations included evidence of fortifications and mysterious earthworks called geoglyphs

Jos Iriarte

More than one in 10 people were found to have traces of class A drugs on their fingers by scientists developing a new fingerprint-based drug test.Using sensitive analysis of the chemical composition of sweat, researchers were able to tell the difference between those who had been directly exposed to heroin and cocaine, and those who had encountered it indirectly.

Getty

The storm bigger than the Earth, has been swhirling for 350 years. The image's colours have been enhanced after it was sent back to Earth.

Pictures by: Tom Momary

Included in Wellcome Image Awards, this 3D image of an African grey parrot shows the highly intricate system of blood vessels.

Scott Birch. Wellcome Images

Another Wellcome Images Award winner, this time of baby Hawaiian bobtail squid. The black ink sac and light organ in the centre of the squids mantle cavity can be clearly seen.

Macroscopic Solutions. Wellcome Images

Of course, the doctor proverb shouldnt be taken literally, but the overall sentiment is true: eating vegetables and fruits daily does have health benefits. Thats because the combination of fibre, vitamins, minerals and phytonutrients may help reduce inflammation and combat cardiovascular disease and some types of cancer.

Carrots are good for your eyes

This narrative traces back to the SecondWorld War. In 1940, British royal air force pilots began using radar to shoot down enemy planes in the dark. To keep this new technology a secret, the Ministry of Informations propaganda was that the pilots had great visual accuracy because they ate carrots, which improved their night vision.

Many children have to be threatened with the possibility of poor eyesightbefore they eat their carrots(Getty)

It seemed plausible, too, because carrots are rich in the antioxidant beta carotene, the precursor to vitamin A. Once absorbed by the body, vitamin A helps make rhodopsin, a pigment that helps eyes work better in low light. Carrots can help if you have vitamin A deficiency that causes poor night vision, but of course they cant really help you (or air force pilots) see in complete darkness. So, yes, carrots are good for eyesight, but other foods rich in beta carotene, such as sweet potatoes, squash and leafy green vegetables, have the same benefits.

Turkey makes you tired

Weve all heard this one after Christmas dinner: The turkey made you fall asleep! Turkey contains an amino acid (a building block of protein) known as tryptophan, which the body uses to generate serotonin, which helps promote sleep. So then there must be something to this whole turkey-sleep connection, right?

Not so fast. Turkey contains no more tryptophan than beef, eggs, fish or chicken, and tryptophan has a hard time getting past the blood-brain barrier, so its not an effective sleep inducer on its own. But the effect of tryptophan increases when insulin levels are high, as happens after you eat a carb-rich meal such as a Christmasdinner with stuffing andpotatoes. So its actually carbs that increase serotonin levels and help with the production of the hormone melatonin, which makes you sleepy. Eating a large meal can have a similar effect because theres increased blood flow to the stomach for digestion, and decreased blood flow to the brain. So its definitely not just turkey that makes you sleepy.

Ginger is also believed to help chronic indigestion and muscle pain (Getty)

Ginger relieves nausea

This remedy has strong roots. More than 5,000 years ago, people from India and China used ginger as a tonic to treat many ailments. The most common and well-established historical use is to alleviate nausea and vomiting. Today, many clinical studies support the use of ginger for exactly this purpose.

Research shows that ginger helps relieve nausea and vomiting caused by motion sickness, morning sickness in pregnancy, during chemotherapy treatments and post-surgically after anaesthetic. Its thought that the constituents in ginger including gingerols and shogaols help speed gastric emptying, which relieves nausea. Some people sip ginger tea for relief, while others prefer to take a ginger capsule, and studies show that both options can work. My mum used to open a can of ginger ale when I was queasy. While she was on the right track, it turns out many soda brands use artificial flavouring rather than real ginger, so those are of little benefit.

Only the best news in your inbox

Fish can be one of the most diverse and budget-friendly proteins (Getty)

Fish is good for your brain

The rest is here:
Does an apple a day really keep the doctor away? The health myths that are just that - The Independent

If you are feeling lethargic or anxious and have gained weight, your doctor might recommend a thyroid function test. These are a series of blood tests that are used to measure how the thyroid gland is functioning. Thyroid hormone affects a persons physical energy, temperature, weight and mood.An estimated 42 million people in India suffer from thyroid diseases, so it is important to get a thyroid function test, especially if you are in the high risk category. Women and old people are at a higher risk of hypothyroidism.What are thyroid function tests?

The thyroid gland produces thyroid hormones triiodothyronine (T3) and thyroxine T4) and a thyroid function test is recommended to assess the levels of these two hormones.

The thyroid panel (test package) also includes a test for thyroid stimulating hormone (TSH), which is produced by the pituitary gland. This hormone helps in regulating the hormones produced by the thyroid gland.

A TSH test is used to determine the underlying cause of abnormal thyroid hormone levels. It is also used to screen for an underactive or overactive thyroid gland.

Are you at risk of thyroid?

T4 and TSH tests are routinely performed on newborns to identify low-functioning thyroid gland. If you are 35 and above or have any risk factors of thyroid disease, it is advised to undergo a screening for thyroid every five years or as prescribed by your doctor.

In addition to high-risk groups, doctors may recommend thyroid screening for patients:

-With a swollen neck (due to an enlarged thyroid gland).-Who have had surgery or radiation therapy, which might have affected the thyroid gland.-With Type 1 Diabetes Mellitus.-With family history of autoimmune thyroid disease.-With psychiatric disorders.-With Downs or Turner Syndrome.

What is the normal range of T3, T4 and TSH?T3: 100200 nanograms per deciliter of blood (ng/dL)

T4: 4.5 11.2 micrograms per deciliter of blood (mcg/dL)

TSH: 0.4 5.0 milli-international units per liter (mIU/dL)

However, if you already have thyroid disease, then the normal range of TSH should be 0.5 3.0 milli-international units per liter.

Overnight fasting is required before undergoing the test. Also, if you are on steroids or taking oral contraceptives, inform your doctor about the same as it might interfere with the test reports.

Understanding the test resultsUsually, T4 and TSH results are used to derive at a diagnosis. However, T3 can help if T4 and TSH suggest hyperthyroidism or if your thyroid levels are not elevated but you might be showing signs and symptoms of hyperthyroidism.

Patterns of thyroid function tests during an assessment of thyroid function are:

Normal thyroid (Euthyroid)

T3: Normal

T4: Normal

TSH: Normal

Overactive thyroid (hyperthyroidism)

T3: High

T4: High or normal

TSH: Low

Underactive thyroid (hypothyroidism)

T3: Normal or low

T4: Low

TSH: High

Thyroid tests next steps

If the test reports are normal, even then diet modifications such as vitamin and mineral supplements may be recommended by your doctor.

DISCLAIMER:This article is authored and provided by The Times of India Healthy India Fit India partner, 1mg.

Continued here:
Thyroid function test: Know what T3, T4 and TSH mean - Times of India

A visit from a dog can reduce the distress of patients waiting for emergency treatment in hospital, a study by the University of Saskatchewan (USask) shows.

Patients who spent 10 minutes with a visiting therapy dog--a four-year-old springer spaniel named Murphy--reported they felt more comfortable, happier and less distressed while waiting for emergency care in hospital.

The study, published in thePatient Experience Journal, found a significant increase in comfort levels and positive feelings after spending time petting, cuddling or interacting with the experienced canine.

The study was carried out at the Royal University Hospital (RUH) in Saskatoon, Saskatchewan--the first emergency department in Canada to introduce therapy dogs to improve the experience of waiting patients.

There is growing evidence that therapy or comfort dogs can be beneficial to human health and can reduce anxiety, heart rate and blood pressure. Interaction with a dog increases production of dopamine, a neurotransmitter, which reduces the stress hormone cortisol.

Professor Colleen Dell, Research Chair in One Health & Wellness at USask's College of Arts and Science, co-led the study with emergency physician Dr. James Stempien, MD, Provincial Department Head, Emergency Medicine in Saskatchewan. The research was supported by the Saskatchewan Centre for Patient-Oriented Research.

"Emergency departments are hectic and confusing places. Most people waiting for treatment feel nervous, and waiting can increase their pain. It is well-known that interacting with animals can help humans feel calm and relaxed. Our study showed a noticeable improvement in the patient's mood after interacting with a therapy dog," Dell said.

"With waiting times consistently high in emergency departments, it suggests that therapy dogs may have a broader therapeutic role to play comforting patients in distress and pain."

RUH is the first emergency department in Canada to allow therapy dogs to visit, with up to six trained therapy dogs now visiting several days a week.

Patients met the dog for between 10 and 30 minutes and included people with cardiac complaints, fractures, psychiatric issues, and those suffering chronic pain.

The 124 patients were waiting in curtained-off cubicles and found their distress levels decreased, and their perceived comfort levels increased after interacting with the spaniel, a certified St. John Ambulance Therapy Dog and its handler. The distress of patients meeting Murphy decreased regardless of the length of their wait.

Patients filled out questionnaires about their well-being and feelings before and after meeting Murphy. The most common themes were feeling 'happy', 'okay', 'better' and 'calm', and 80 per cent expressed happiness during the visit and said they felt calmer after the visit.

Sixty six per cent of those visited by Murphy patted him, stroked him or cuddled him. One patient gave the dog a massage and some snuggled up to him or let the dog put his head on their chest. In almost a quarter of cases, the dog's 'intuition' when interacting with a patient was noted.

Logan Fele-Slaferek, a co-author of the paper and patient advocate, met Murphy on several occasions while an RUH inpatient for a recurrent health condition. On one occasion, after a six-month-long treatment program had failed and he was feeling 'crushed and hopeless', the spaniel jumped on Logan's lap and fell asleep.

"I was a little skeptical about his helping at first, but that all changed five minutes later. The dog picks up on your mood or temperament better than most people would. He helped my recovery immensely. It's something about being next to an animal that exudes nothing but love and kindness," Fele-Slaferek, an undergraduate at USask, said. "The emergency department can be so hectic, but time slows down when you are with a therapy dog. His presence is soothing."

Jane Smith, Murphy's handler, said it is clear the therapy dog enjoys meeting the patients, and sometimes does not want to leave them.

"When Murphy enters the emergency department, the mood changes quickly. You can see patients, doctors, and staff smiling, even before he actually visits anyone," she said. "During the visits he looks at patients with big, brown eyes, settling in to enjoy the pets and cuddles. Sometimes, Murphy needs extra encouragement to leave a patient. It is actually hard to tell who enjoys the visit more."

This preliminary study has led to Dell and her team being awarded a research grant of $20,000 from the Royal University Hospital Foundation to undertake further research at RUH into the impact of therapy dog visits on adult emergency department patients and their experiences of pain.

Read more here:
Dogs reduce distress of patients waiting for emergency hospital care - Jill Lopez

(Pregnancy Help News) Recently, a Tennessee woman gave birth to healthy twin babies who miraculously survived a chemical abortion attempt at a Knoxville, TN, Planned Parenthood.

The incredible story of these miracle babies, as told by one pro-life physician, underscores just how sorely the abortion giant fails to meet the needs of women, both from a medical standpoint and a human one.

Displaying obvious ineptitude from the start, the nations largest abortion business only informed the woman she was pregnant with twins after the chemical abortion shed been given by Planned Parenthood staff failed.

Furthermore, at her initial visit to the Planned Parenthood facility, the staff misinformed her about the basic biological development happening within her seven-week pregnancy, stating that it was too early for a heartbeat and that it was just cardiac activity they were seeing.

Pro-life physician Brent Boles, who helped the woman following her failed abortion, commented on Facebook earlier this month about the twins birth and Planned Parenthoods handling of the pregnancy.

Abortion isnt about caring for the woman, Boles said. Its about the $$$.

Boles had originally shared the story on the social media platform this past March after the woman contacted him looking for help.

Boles, who is a member of the Abortion Pill Rescue Network, told Pregnancy Help News that his patient originally came to him through the groups 24/7 helpline (877-558-0333). She had found the helpline after returning to Planned Parenthood for a follow-up appointment and discovering that she was still pregnant.

READ:Pro-choice? Media slams miscarriage-halting hormone when used to reverse the abortion pill

Because Planned Parenthood had no help to offer her, she left and scoured the web before landing on AbortionPillReversal.com.

From the doctors October 4 post:

Earlier this year, a patient called the Abortion Pill Rescue hotline and was referred to me. Three weeks before, she had been in a Planned Parenthood facility. She had an ultrasound at seven weeks, and asked during the ultrasound if there was a heartbeat. She was told No, its too early to call it a heartbeat; it is just cardiac activity.

As he did in his Facebook post this past March, Boles lambasted the abortion industry cardiac activity lie in his new post about the twins:

Problem #1: those types of statements are just deceptive word games. Calling the fetal heartbeat embryonic pulsing or cardiac activity and saying that it is not yet a heartbeat is a lie. The leading textbooks of embryology say that the heart begins to beat at five weeks and they call that a heartbeat. No medical or scientific text affirms their erroneous concept that pulsatile activity is not yet a heartbeat. In fact, those texts say that the cardiac/circulatory system is the first organ system to perform its adult purpose in utero. They lied to her in order to have her emotionally commit to handing over her cash and having the abortion.

That wasnt the only problem with Planned Parenthoods so-called medical evaluation of his patient:

Problem #2: at seven weeks the vast majority of competent sonographers will never miss twins at that point. But women who find out they are having twins are far less likely to abort twins, as the thought of aborting only one baby does t seem quite as bad as aborting two. So either an incompetent sonographer missed the fact that she had twins or didnt want to tell her and have her thousand dollars walk out the door with her.

She did the course of the abortion pill and nothing happened. She went back two weeks later and had another ultrasound at approximately nine weeks and they said oh well, it didnt work, and you are having twins. She asked what could be done and they said nothing. She left, found the number to call on google, and that led her to my office.

Abortion Pill Reversal, which has saved more than 900 babies to date, works by giving pregnant women additional progesterone, a natural hormone that sustains a healthy pregnancy. In the case of a twin pregnancy, a womans body produces more progesterone to nurture both babies.

In evaluating his patient and the twins, Boles determined that in this case, extra progesterone via Abortion Pill Reversal wouldnt be necessary. But for Boles, that still didnt excuse Planned Parenthoods glaring incompetence when it came to administering a practice he strongly opposes:

Problem #3: they (Planned Parenthood) dont even know how to use the medication properly, assuming they did know it was twins. I am prolife and I know that a higher dose of mifeprex is required to work successfully to abort a multiple gestation, because a twin pregnancy produces higher levels of progesterone.

For Christa Brown, director of Medical Impact at Heartbeat International, the twins survival, as well as other survivals achieved through the Abortion Pill Rescue Network, marks a notable victory for life.

Its incredible to think that the abortion industry has already counted those babies as abortion statistics, but instead they are alive and well, she said. We are so thankful for Dr. Boles and all of the providers in the Abortion Pill Rescue Network who are saving lives every single day worldwide. To date, the abortion industry has lost nearly 1,000 of their statistics and our world has gained nearly 1,000 precious babies who are growing and thriving thanks to the APR Network.

Not only did Planned Parenthood fail this woman in every medical aspect, but the abortion business also failed to meet her basic human needs as a pregnant woman now expecting twins. Boless final critique of the abortion giant?

Problem #4: they refused to offer any advice or counsel.

For several years now, abortion advocates have fired off endless lies about the help provided by pro-life pregnancy help organizations. But who is really taking care of women in unexpected pregnancies?

More than 2,750 pregnancy help centers all across the U.S. are providing counsel and resources to women in need every day. From diapers to housing to parenting classes to free obstetrical ultrasound scans, they are serving families from a place of utmost compassion and care.

READ:Abortion pill reversal saved her baby after she regretted taking the first dose

In 2017, they served nearly 2 million clients, saving communities, an estimated $161 million.

When the abortion industry fails to meet womens needs, pregnancy centers are there. When a woman is kicked out of her home and has nowhere to go, maternity homes are there. When the abortion industry leaves a woman grieving and regretting her choice, abortion recovery ministries are there.

When a woman desperately wants to save her unborn child from an in-process chemical abortion, Dr. Boles and hundreds of other pro-life physicians in the Abortion Pill Rescue Network are there, offering her child one last chance at life.

Despite Planned Parenthoods utter failure to meet this patients needs, today two healthy babies are alive and doing well in the state of Tennessee.

These twins have now delivered at term, uncomplicated by any other issues, Boles wrote in his social media post, and are at home with their parents, who are exceedingly pleased that a decision made under pressure and while in fear did not work out as planned.

PHN Editors note: The AbortionPillReversal.com program, the Abortion Pill Rescue Network (APRN) and Pregnancy Help News are managed by Heartbeat International.

Editors Note: This article was printed at Pregnancy Help News and is reprinted here with permission.

Like Live Action News on Facebookfor more pro-life news and commentary!

Read more:
Planned Parenthood didn't tell her she was pregnant with twins. Then, they survived the abortion pill. - Live Action News

A solid eight hours can be hard to come by in our non-stop, tech-saturated world. But the modern science of sleep shows that shut-eye is just as critical as diet and exercise in shaping both mental and physical health.

Host Rao is joined by Mary Ellen Wells, the director of the neurodiagnostics and sleep science program at the University of North Carolina School of Medicine; Jade Wu, a licensed clinical psychologist at Duke University specializing in behavioral sleep medicine; Roger Ekirch, a university distinguished professor in the department of history at Virginia Tech; and Sheena Faherty, a science communicator who conducted doctoral research into hibernation in lemurs at the Duke Lemur Center to talk about sleep on this edition of 'Embodied.'

On this episode of The State of Things series Embodied: Sex, Relationships and Your Health, host Anita Rao speaks with experts in psychology, neurology, history and even lemur biology to better understand what is actually happening when we sleep and how we can learn to sleep better.

If I had no social obligations, no work and I lived in a cave, I would just want to go to bed later and later each day and wake up later and later each day. -Jade Wu

Rao is joined byMary Ellen Wells, the director of the neurodiagnostics and sleep science program at the University of North Carolina School of Medicine;Jade Wu, a licensed clinical psychologist at Duke University specializing in behavioral sleep medicine and the host of the Savvy Psychologist podcast;Roger Ekirch, a university distinguished professor in the department of history at Virginia Tech and the researcher who brought to light an ancient pattern of segmented sleep; andSheena Faherty, a science communicator who conducted doctoral research into hibernation in lemurs at the Duke Lemur Center.

The sleep experts break down the latest research into the science of sleep, how our ancestors used to sleep in two shifts with a period of wakefulness in between, and why lemurs may hold the key to human hibernation and deep space travel.

Interview Highlights

Jade Wu on whats happening to our brains and bodies during deep sleep:

Human growth hormone peaks in how much it's being released in the body during deep sleep. So that's why kids need a lot of sleep, need a lot of deep sleep because they're growing. Sex hormones are also being released during this stage. That's why teenagers also need a lot of sleep, because they're going through puberty. And we're also consolidating memories The brain is also doing some janitorial work very important janitorial work. We're clearing out debris from the cerebrospinal fluid, just basically junk in the brain that we don't need. And with this clearing out, we're sort of resetting and we're maintaining brain health.

Wu on how we are programmed to have different circadian rhythms:

We are all biologically wired to be either a morning lark, a night owl or somewhere in the middle. And this is largely driven by genetics, so we can't help it. And there's actually differences in the length of our cycles depending on what we have. So for example, I'm a night owl. So I probably don't have a 24 hour cycle I probably have something more like a 24.3 hour cycle. Meaning if I had no social obligations, no work and I lived in a cave, I would just want to go to bed later and later each day and wake up later and later each day. Whereas people who are morning people tend to have closer to a 24 hour cycle. Though the average I believe, is about 24.1 hours.

Mary Ellen Wells on the science behind sleepwalking:

So sleepwalking, it can be surprisingly common about one to 15% of the population can suffer from sleepwalking at any point. And it's more common in children. And it's one of what we call a parasomnia, [those] are essentially acting out or movements, odd things that are happening during the night ... And there are certain parasomnia that happen during REM sleep and certain parasomnia that happen during non-REM sleep. Sleepwalking is one of those that happen during non-REM sleep. REM sleep is essentially your dreaming state. And sleepwalking it's not entirely understood exactly why this happens to people. But there are many things that can spark it to happen, such as sleep deprivation Sleepwalking is very, very dangerous. The person [is] not aware that this is happening. So there's a misperception out there that you should never wake a sleepwalker.

It was a prime time for petty crime. -Roger Ekirch

Roger Ekirch on what people did in the break between segmented sleep:

There were special prayers to be said after your first sleep. They meditated, many reflected upon dreams from whence they had just awakened. Others of course, used chamber pots. But then, still others left their beds, they performed chores. There's a wonderful passage in Virgil's Aeneid describing this. [They] performed chores that required very little light and virtually no skill in the dead of night. Some left their homes, visited neighbors or I think even more commonly pilfered apples from a neighbor's orchard. It was a prime time for petty crime. It was also, in the view of physicians writing in the 16th, 17th and 18th centuries, a prime opportunity in which to conceive children, after the first sleep when a couple would be more rested. In the words of Laurent Joubert, a French physician in the 16th century: It is after the first sleep when couples and I'm quoting him verbatim do it better and enjoy it more.

Sheena Faherty on the question of whether humans could possibly hibernate one day:

NASA is really interested in it because of things like space travel. And these types of things have applications to emergency medicine and organ transplantation....What we find is that the same metabolic pathways, and genes that are involved in these metabolic pathways that are regulating these changes in metabolism [during lemur hibernation], are the same genetic pathways and genes that humans have already. And so in theory, humans have the capability to enter a torpor-like state based on this finding.

Original post:
Embodied: The Elusive Science Of Sleep - WUNC

When the Below Deck crew from Valor went out on the town, bosun Ashton Pienaar observed that it seems easy to get into a lot of trouble in Thailand. Thailand is a lot of fun, he says in a confessional. But you can get into a lot of trouble. I think they put something different in their vodka?

The next day after sleeping on the deck, Pienaar exclaims, I feel rough. Meanwhile, chief stew Kate Chastain, who didnt appear to be overly intoxicated the night before searches for medicine to help with her hangover. She is filmed in the fetal position on a couch. I think the vodka in Thailand is different, she says in a confessional. This is like 18-year-old Kate partying and hungover. Its not a good look.

Later one of the guests on the next charter gets extremely drunk before she even boards the yacht. Previews for an upcoming episode catch her being so drunk in another instance, she needs medical attention. What is it about Thailand that has the crew and guests getting so drunk?

While yachties may be used to tropical conditions, Below Deck cast members often remark about the intense heat in Thailand. The problem with drinking in extreme heat is that booze becomes a diuretic, which drains the body of fluids. People think of alcohol as a thirst-quencher because it comes in a refreshing, cold liquid. But in hot weather, youre already losing fluids through sweat and through exercise, Dr. Josef Thundiyil, an emergency physician with Orlando Regional Medical Center told The Epoch Times.

What ends up happening is people urinate more often in the hot weather and get dehydrated faster. You end up peeing out more than you take in, he said. Once you start drinking alcohol, you shut that hormone off, so its not as simple as making up for it by drinking more water. Youre going to continue to urinate more than you normally would if you hadnt been drinking alcohol.

Combine heat with booze and it could be a recipe for trouble. Thundiyil says that alcohol depresses the hypothalamus, which is the gland thatregulates body temperature. As a result, drinking in the heat means youll feel hotter (and perhaps drink more). Impaired judgment is a big issue because a lot of times people dont know exactly how unclear their decisions actually are, he said. Even if people may not achieve the legal driving limit, .08 in most states, you can still have ill effects. You can lose judgment and coordination, and that can give way to things like more significant inebriation.

The heat sounds pretty brutal just from the comments coming from the crew. Thailand is an especially hot destination but extremely hot during the months when Below Deck was filming.

The weather doesnt cool off much at night, although higher elevations in some areas make it more bearable than in the rest of the country, according to Trip Savvy. During the hot season, visitors can expect highs to reach above 90 degrees Fahrenheit (32 degrees Celsius), with some sweltering days even hotter.

Like many places in the world, Thailand experienced an increase in temperatures over the last several years. Temperatures have reached such significant heights in the past, animals at the Dusit Zoo in Bangkok were at risk of overheating.

More here:
'Below Deck': Why Is Drinking Alcohol in Thailand Getting the Crew and Guests so Drunk? - Showbiz Cheat Sheet

Consumer genetic tests could be giving false reassurance to those at heightened risk of cancers, according to findings presented at an international conference this week.

The study, by clinical genetic testing company Invitae, revealed that tests for breast and bowel cancer risk by direct-to-consumer companies such as 23andMe give negative results to the vast majority of those carrying DNA mutations in the genes under investigation.

These tests should not be taken at face value at all, whether they are positive or negative, said Edward Esplin from Invitae ahead of the annual meeting of the American Society of Human Genetics in Houston, Texas.

The data really underscores that there needs to be increased awareness that results from this type of screening may not be wrong but theyre woefully incomplete.

The research also showed that those from Asian and African-American backgrounds were more likely to carry mutations that were not designed to be detected by the consumer tests.

The research focused on DNA-based tests relating to breast, ovarian and bowel cancer that were recently approved by the US Food and Drug Administration.

The tests operate by a subject sending a DNA swab in the post for analysis and then receiving results with information about how their genetics could influence their health.

In the case of breast and ovarian cancer, the FDA has approved a screening test for three specific mutations on the BRCA1 and BRCA2 genes, which are most common in people of Ashkenazi Jewish heritage. However, these mutations are rare in people from other backgrounds.

Similarly, for bowel cancer, 23andMe offers FDA-authorised tests for two mutations, which are most common among individuals of northern European ancestry. The company explains the limitations of these tests to consumers and on its website.

Esplin said that despite this, consumers could be wrongly reassured by a negative result.

The study analysed the DNA of 270,806 patients who had been referred by healthcare providers for testing of the MUTYH gene, and 119,328 who had been referred for BRCA1/2 genetic testing.

It showed that for both tests, the majority of those carrying mutations would not be spotted, which Invitae describes as a clinical false-negative result.

For MUYTH, 40% of individuals with mutations in both copies of their MUTYH genes consistent with an almost 100% lifetime risk of bowel cancer had different mutations to those screened for in the FDA-approved test. This figure rose to 100% for those from Asian backgrounds and 75% for African-Americans.

For BRCA genes, 94% of non-Ashkenazi Jewish individuals and 19% of those of Ashkenazi heritage had a mutation that would be missed. Again, the figures were highest for those of Asian (98%) and African-American (99%) ancestry. Its performing a disproportionate disservice to individuals of these underrepresented groups, Esplin said.

A clinical false-negative result can be incorrectly reassuring, excluding a patient from receiving the preventive care they need based on their risk, he added. It could be the difference between preventing cancer and developing cancer.

In response to the findings, 23andMe said in a statement: The claims made by a competitor that we are returning clinical false negatives is incorrect and a false characterisation of 23andMes test. Our test is extremely accurate. As part of the FDA authorisation process weve demonstrated over 99% accuracy for the variants we test for in our health product.

The company said it makes clear to customers that it tests only for certain genetic variants and that customers should not forgo any recommended testing based on 23andMe results. 23andMe is not a diagnostic test, the company said. If an individual has a family history of cancer or other indications for clinical testing we always recommend consulting a healthcare provider first.

Prof Anneke Lucassen, a clinical geneticist at the University of Southampton, said that, in her experience, non-specialists would be likely to wrongly interpret negative results as an all-clear.

I do think the false-negative rate is an issue, not necessarily through the companies fault but through low general awareness, she said. Most people who come to clinic ask: Have I got the gene for breast cancer? and imagine its a single test, not that the test involves looking through around 20,000 letters of the genetic code to see if any one of them might be different.

Read more:
Genetic testing kits 'may wrongly reassure those at risk of cancer' - The Guardian

Myriad Genetics is among a handful of companies that make a genetic test to help doctors choose psychiatric medicines for patients. Evidence that the tests are effective has been called "inconclusive." Myriad Genetics hide caption

Myriad Genetics is among a handful of companies that make a genetic test to help doctors choose psychiatric medicines for patients. Evidence that the tests are effective has been called "inconclusive."

As a teenager, Katie Gruman was prescribed one mental health drug after another. None seemed to help her manage symptoms of anxiety and bipolar disorder, so she self-medicated with alcohol and illicit drugs.

It would take five years, and trying more than 15 different medications, before she found meds that actually helped.

Now 28 and in recovery, Gruman has been on the same drugs for years. But when a clinician recommended a genetic test to see which drugs work best for her, she took it.

Reading the test results "was definitely vindicating," she says. Medications that hadn't worked for her as a teenager were the same ones the results marked as bad fits.

She says she wishes she had taken the test as a teenager. "I could have avoided a lot of disaster in my life," she says.

Psychiatric medications are known to be hard to match to symptoms, and many patients like Gruman live through years of trial and error with their doctors.

Companies that make genetic tests like the one Gruman used say they can save patients and doctors from prolonged searching for the right medication and save insurance companies from paying for ineffective drugs. But many researchers say the tests don't have enough evidence backing them up. The Food and Drug Administration has warned that the tests could potentially steer patients towards the wrong medications. Nonetheless, UnitedHealthcare, the nation's largest insurer, began covering them October 1 for its 27 million individual and group plans.

Test makers hailed the announcement of United's coverage, the first from an insurance company to apply to all of its commercial plans across the country.

"We expect this to be a tipping point," says Shawn Patrick O'Brien, CEO of Genomind, a company that makes one of the tests. Other insurers will cover the tests "because they don't want to be uncompetitive in the marketplace," he predicts.

If the prediction is correct, it would likely fuel a market that has seen its largest test maker, Myriad Genetics, sell about 375,000 of its psychiatric medicine tests in the 2019 fiscal year, according to Jack Meehan, an industry analyst for Barclays. Myriad reported that it sold $113 million worth of the tests.

In addition to UnitedHealthcare's coverage, Myriad Genetics' test is covered by Medicare, a regional Blue Cross Blue Shield affiliate, and the insurance network for the grocery chain Kroger, a spokesperson says.

Genomind has discussed coverage with insurers including Anthem and Blue Cross Blue Shield, O'Brien says.

Debates over efficacy

As the field of genetic testing to help diagnose and treat disease grows, medicine has embraced certain tests, such as that for the BRCA gene linked to breast cancer. But many researchers say there is not enough evidence tying genetic variants to better outcomes for most psychiatric medications.

James Potash, the head of psychiatry at Johns Hopkins Medicine and an expert on psychiatric genetics, says of all the tests claiming to improve depression treatment, GeneSight's has the most proof. That isn't saying much, though.

"I wouldn't say there's no evidence that it works," he says. "It's just the evidence at this point is still weak."

The idea behind the tests is that in some cases, people can have different reactions to the same drug, even at the same dose, because they have different gene variants. Which variant a person has can affect how quickly or slowly a medicine moves through their body.

This link between genes and drug metabolism has been known for decades, says Francis McMahon, who leads genetic research into mood and anxiety disorders at the National Institutes for Mental Health.

Usually, the longer it takes your body to process a drug, the easier it is for that medication to have an effect. But in psychiatry, McMahon says, how fast someone processes a drug, or metabolizes it, and how well they respond to the drug "are sometimes not strongly related."

This skepticism is shared by some insurance companies. "Anthem considers these tests investigational and not medically necessary," says a spokesman for the carrier, which covers 41 million people. The Blue Cross Blue Shield Federal Employee Program, which covers about two-thirds of government workers and their families, said "there is not enough evidence at this time to determine the effect of genetic testing on health outcomes," according to a spokeswoman.

Test makers are also facing FDA objections that they haven't proven some of the claims underpinning genetic tests for medications, including that antidepressants work better with some gene variants.

"Changing drug treatment based on the results from such a genetic test could lead to inappropriate treatment decisions and potentially serious health consequences for the patient," the agency warned in late 2018. It told companies to stop naming specific drugs, in marketing materials or test results, for which its tests "claim to predict a patient's response" without "scientific or clinical evidence to support this use."

Most test makers complied. One, Inova Genomics Laboratory, stopped selling a range of tests, including its test for mental health disorders, after the FDA followed up with a warning letter in April.

Several mental health advocacy groups, including the National Alliance on Mental Illness, have sided with test makers in their dispute with the FDA. Keeping the names and types of medication off of genetic test reports, as the FDA has required, will "impede the ability of psychiatrists and other front-line health care professionals to personalize medication decisions" for patients with depression, the groups wrote the FDA in September.

Some have argued that genetic tests like these shouldn't be regulated by the FDA at all. Tests conducted in a lab are a medical service, not a medical device that's shipped like a product, says Vicky Pratt, president of the Association for Molecular Pathology. As a medical service, she says, clinical laboratories are already regulated by the Centers for Medicare and Medicaid Services.

"It would be redundant to have dual regulation by both the FDA and CMS," says Pratt.

Cost-benefit analysis

Research into the tests' efficacy is ongoing and continues to be debated.

Myriad hoped to bolster evidence for its test, GeneSight, in a study it funded that was published this year in the Journal of Psychiatric Research, but the results were mixed.

In the study, doctors used genetic tests to help prescribe medications for one group of patients with depression, while another group of patients received usual care. There was overall no difference between the groups in the study's primary measure of symptom improvement, though some patients showed improved response and remission rates.

Responding to criticisms of its clinical trial results, Myriad Genetics spokesman Ron Rogers says the trial population whose average participant had tried more than three unsuccessful medications for depression was uniquely difficult to treat. He says he expects to see stronger outcomes in a forthcoming review of the trial data.

In a statement on the use of genetic testing in psychiatry, the International Society of Psychiatric Genetics, calls the existing evidence "inconclusive," and notes that if 12 patients take such a test for antidepressants, just one will benefit from it.

A low rate of success means insurers will have to pay for a lot of tests for one useful result, says Barclays analyst Meehan. Meehan pointed to a letter about the recent GeneSight study that was published in the same journal, which found that 20 patients would need to take the test for one to recover as a result. At $2,000 for a GeneSight test, the authors wrote, that means patients and insurers would have to cover $40,000 worth of tests. (While competitor Genomind does not share pricing information, a spokeswoman confirmed that it has an active contract with the Department of Veterans to supply tests for $1,886.)

Still some clinicians value the tests. Skeptics often misunderstand how the tests should be used, argues Daniel Mueller, a professor at the University of Toronto who researches how genes and drugs interact. (Mueller is involved in research comparing Myriad's GeneSight to another test developed by a University of Toronto-affiliated hospital.) Most of the time, he says, doctors who order the test already plan to prescribe medication. The test is just another tool to help them decide which one to prescribe.

"It's not an alternative intervention," Mueller says. "It's additional information." He orders the test for most patients who do not respond to at least one antidepressant.

"If you think about the cost of depression and weeks of suffering that you can potentially avoid for some patients," Mueller says, he thinks anyone who can afford a test should take it. (Myriad says 95% of patients pay less than $330 for their test, the cost remaining after insurance and possible financial assistance; Genomind says most privately insured customers pay no more than $325.)

A lack of watertight evidence for the tests should not stop doctors from using it to inform their choice of medication, says Reyna Taylor, who leads public policy for the National Council for Behavioral Health, one of the advocacy groups that defended the tests in a letter to the FDA. "You use the science that you currently have," she says.

"Whether our providers choose to use [a genetic test] or not, we want them to have that choice," she adds.

Disagreement among experts hasn't dissuaded UnitedHealthcare from paying for the tests.

In a statement, UnitedHealthcare spokeswoman Tracey Lempner says they "frequently review our coverage policies to ensure they reflect the most current published evidence-based medicine and specialty society recommendations."

Graison Dangor is a journalist in Brooklyn.

The rest is here:
Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News - NPR

According to study findings presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, health reports from direct-to-consumer (DTC) genetic tests that adopt a limited variant screening approach are producing clinically false-negative results.The advances in next-generation sequencing (NGS) technologies that have occurred since the "Genomic Era" mean that DTC genetic testing is now increasingly affordable and more of us are opting to do it. These genetic tests are marketed directly to consumers via an array of advertising platforms, print, television, or the internet; and the tests can be purchased online or in shopping stores. A customer purchases the test, sends the company a DNA sample and receives their results directly there is no intervention from a healthcare provider. DTC companies offer genetic tests for an array of purposes, be it to make predictions about an individual's health, to provide information on common genetic traits, or to offer insight on an individual's ancestry.The popularity of DTC genetic testing has grown to the extent that The U.S. Food and Drug Administration (FDA) has authorized marketing of health reports from DTC genetic screens for genetic risk of breast, colorectal and ovarian cancer.DTC "It's like reading a book"Typically, the tests search for variants in a consumer's genome, such as single nucleotide polymorphisms (SNPs), that can increase an individual's susceptibility to disease. However, concern has arisen as to whether the variant screening provided by DTC companies is thorough enough to yield true clinical value.While limited variant screens may be informative for the variants they detect, they are not designed to detect every variant that has been linked to the disease in question, explained Edward Esplin, MD, of Invitae, who presented the research. "Thus, these health reports may provide a false sense of reassurance and should not be used for making any health decisions without confirmation testing."Esplin told Technology Networks, "The limited health screens available direct-to-consumer state they should not be used for healthcare decision-making, consistent with FDA recommendations. Clinical tests are designed expressly for healthcare decision-making. Rather than looking at a few variants in a few genes, clinical tests provide comprehensive information on the relevant genes and variants proven to confer increased risk of disease. Its like proofreading a book. If each gene is a chapter, a clinical test proofreads the entire chapter on that gene, whereas a DTC test may look for errors in only a few letters."

In the presented study, Esplin and colleagues wanted to quantify the clinical false negatives that result from a limited screening strategy. They therefore focused on two FDA-authorized limited variant screening tests, one for MUTYH gene, which detects to variants linked with colorectal cancer, and one for BRCA1 and BRCA2, which identifies three variants associated with breast cancer.I ask Esplin how we define "limited screening". He tells me, "For tests using limited screening strategies only a small portion of the clinically relevant genetic variants are reported. For example, there are thousands of variants in BRCA1 and BRCA2 that have been shown to increase risk of breast and ovarian cancer in women. Screening tests that provide information on just 2 or 3 of those variants, such as those limited to the 3 BRCA1/2 variants most common in individuals of Ashkenazi Jewish descent, are highly limited. Again, the book analogy is helpful."The scientists studied 270, 806 patients who had been referred by healthcare professionals for MUTYH genetic testing, and 119, 328 who had been referred for BRCA1/2 genetic testing.

For both tests, they identified that if only the limited variant screenings had been performed, then most patients would have received a clinical false-negative result.

Specifically, for MUTYH genetic testing, 40% of individuals with mutations in both of their MUTYH genes (which is consistent with 100% lifetime risk of developing colorectal cancer) would have been missed. 22% of carriers of one MUTYH mutation, which is consistent with a 2-fold increased risk of colorectal cancer, also would have been missed.

When analyzing BRCA1/2 the variants tested were significantly more common amongst Ashkenazi Jewish study participants. However, even among these individuals, 19% would have received a false-negative result, and 94% of non-Ashkenazi Jewish individuals carried a BRCA1/2 mutation that would have been completely missed.

Esplin tells me, "Our study did not evaluate the reasons behind the variation in these populations that we observed. This is an important area for further study. That said, it stands to reason that if a test is looking at just 2 or 3 variants associated with a specific population, such those of Ashkenzai Jewish descent, populations likely to have substantially less of that heritage will exhibit substantially fewer of those variants."

He continues, "A clinical false-negative result can be incorrectly reassuring, excluding a patient from receiving the preventive care they need based on their risk. It could be the difference between preventing cancer and developing cancer."Analyzing differences among populationsEsplin's team analyzed the rate of false-negatives among patients of different ethnic backgrounds. Their results show that for MUTYH, 100% of Asians, 75% of African-Americans, 46% of Hispanics and 33% of Caucasians would have received a clinical false-negative. In parallel, for BRCA1/2, 98% of Asians, 99% of African-Americans, 94% of Hispanics, and 94% of Caucasians would have also received a clinical false-negative.

Collectively, these findings emphasize the medical worth of conducting in-depth, comprehensive clinical genetic testing. "The results from this type of DTC genetic screening may not be wrong but they are woefully incomplete, particularly when viewed against the health question a patient may be asking - am I at risk for cancer. We hope our research underscores the need for consumers to understand the deep limitations of these health reports and seek out appropriate clinical genetic testing when trying to understand their risk of health conditions like cancer," says Esplin.I ask Esplin what his advice would be to individuals considering a DTC genetic test. He tells me: "Think about the question you hope to answer by taking the test. If you are interested in whether you are at risk for a disease, you need a comprehensive, medical grade genetic test that can answer that question and be used by you and your physician to take action on the result. So if you want to know if youre at risk for cancer, you need a comprehensive clinical genetic test that evaluates all of the gene changes that can increase your risk. It is easier than ever before to get the tests genetic experts trust thanks to offerings like ours that link patients to clinicians via telemedicine. If youre interested in getting a health answer, get a medical test."

Reference: ED Esplin et al. (2019 Oct 17). Abstract: Limitations of direct-to-consumer genetic screening for hereditary breast, ovarian, and colorectal cancer risk. Presented at the American Society of Human Genetics 2019 Annual Meeting. Houston, Texas.Edward Esplin, M.D., was speaking with Molly Campbell, Science Writer, Technology Networks

Go here to read the rest:
Limitations of Health Reports From Direct-to-Consumer Genetic Tests Are Identified - Technology Networks

Matthew Knowles, the father of the artists Beyonc and Solange, recently announced that he had been told that he has a breast cancer caused by a BRCA2 gene mutation and that his children have a 50 percent chance of inheriting it.

In 2007, my mother was in a similar position. She learned after receiving a breast cancer diagnosis at age 42 for a second time her first bout with cancer came when she was 28 that she carried a BRCA2 mutation. It meant that as her daughter, I had even odds of having inherited it from her.

BRCA1 and -2 gene mutations can elevate a carriers lifetime risk of developing breast cancer up to 72 percent, compared to a 12 percent lifetime risk among the general population. They can also elevate a carriers lifetime risk of ovarian, pancreatic or prostate cancers along with melanoma. Although he had a family history of breast cancer, Mr. Knowles had never been referred for genetic counseling or testing to evaluate his risk of having a BRCA mutation.

His story is all too common among African-Americans. Black women are substantially less likely to undergo genetic counseling and testing for BRCA mutations as compared to white women, even though research suggests that the rate of BRCA mutations is higher among black women than it is for white.

Researchers at the Moffitt Cancer Center in Florida found that among young breast cancer patients who met the national guidelines for receiving genetic counseling, only 37 percent of black women had discussed it with a provider compared to 86 percent of white women. Just 36 percent of black women received testing for BRCA compared to 65 percent of white women. A study showed that only 58 percent of black women who were eligible for genetic testing under the national guidelines received testing as a part of their routine care.

Although there is no clear answer as to why the disparity exists, one reason may be the lack of awareness among doctors that black people are at risk for carrying BRCA mutations. Ohio State University researchers interviewed black and white women at higher risk for breast cancer. One study participant, a black woman in her 20s, reported that when she had expressed interest in genetic counseling, her gynecologist told her that only Jewish women tested positive for BRCA mutations.

Although its true that Ashkenazi Jews have an especially high risk of carrying a mutation (the rate is estimated to be one in 40), people of all racial backgrounds run a risk. The same study also found that black women are less likely have seen a specialist who could provide information on genetic counseling and testing: only 15 percent of black women in the study had met with a genetics, cancer or breast specialist as against 70 percent of white participants.

Although there have not been any published studies that I know of on genetic counseling and testing rates among black men, a 2016 report found that among men diagnosed with prostate cancer, black men may be more likely to have BRCA1 and BRCA2 mutations than white men.

The discovery of the BRCA1 and -2 mutations in 1994 and 1995 was a huge breakthrough that allowed for us to get better at treating and preventing cancer. That makes the low levels of BRCA testing among African-Americans especially troubling, because people who know they are carriers can possibly reduce the risk of getting cancer by getting a preventive mastectomy or oophorectomy.

I know this myself. When I was 29, I was tested and discovered that my mother had passed on her BRCA2 mutation to me. I decided to have a preventive double mastectomy, which shrank my risk of developing breast cancer from 80 percent to less than 5 percent.

Even if a person decides not to do what I did, enhanced surveillance, like an MRI and mammogram every six months, can help detect cancer at an early stage when its more treatable. If black women and men arent receiving genetic testing, theyre potentially missing out on the chance to catch breast cancer early on. This is crucial because black women are more likely than white women get diagnoses of breast cancer at a later stage, which has lower survival rates. Similarly, black men are also more likely than white men to be told they have prostate cancer when it has reached a more advanced stage.

As the use of personalized medicine and genomics in treating cancer increases, knowing whether a patient has a BRCA mutation allows for individualized treatment. It also lets the patient to take steps to prevent a recurrence or a second cancer elsewhere. For example, once my mother learned that she carried a BRCA2 mutation, which is also associated with a higher risk of ovarian cancer, she underwent an oophorectomy. She has been cancer-free for 12 years.

Knowing that a person carries a BRCA mutation also provides an opportunity to test and identify relatives who may carry a harmful mutation potentially preventing and detecting cancer early in a whole family.

We need a large-scale effort to improve genetic counseling and increase testing rates in the black community. The first step is to make medical providers more aware that black women and men are at risk for carrying BRCA mutations. Numerous studies have shown that the biggest indicator of whether someone undergoes genetic testing is a recommendation from a doctor.

An educational effort would also help to dispel myths that genetic testing is financially prohibitive. Most insurance will cover the costs of testing for people who meet the national guidelines. When I underwent testing in 2014, I paid only $80 after insurance kicked in.

Cancer awareness organizations also need to do a better job of reaching out to the black community about BRCA mutations and the benefits of genetic counseling and testing. Research shows that black women are highly interested in undergoing testing for BRCA mutations once they are presented with information regarding its benefits.

Only one percent of genetic counselors in the United States are black. We need more black health care professionals who have undergone specialized training to provide risk assessment and interpret genetic testing results. This could also help to increase the number of black women who receive genetic testing.

I cannot imagine what it must have been like for my mother to have faced her first cancer diagnosis when she was not even 30 and had a young daughter. What I do know is that I was able to substantially lower my chance of having to battle the same disease because I knew about her BRCA2 mutation. More black families should be empowered with the same information.

Erika Stallings (@quidditch424) is a lawyer.

Follow this link:
Beyoncs Dad Has a Mutation More African-Americans Should Be Tested For - The New York Times

NEW YORK - Singer Beyonce Knowles poses with her father and manager Matthew Knowles June 23, 2005 ... [+] (Photo by Frank Micelotta/Getty Images)

Beyonces father, Matthew Knowles, recently went public with the announcement that he has breast cancer and carries a mutation in a gene called BRCA2.He joinsAngelina Jolieas a celebrity who has shared his private medical and genetic history in order to raise awareness and potentially help millions of patients and health care providers.

Knowless story has several unusual twists. First,he is a man with breast cancer. Many people still dont realize that men can develop the disease,which affects approximately 1 in every 1,000 men every year. Because men, and their health care providers, are not as aware of the prevalence of the disease in men, male breast cancer is often diagnosed at later stages and is associated with aworse prognosis.Any male who has bloody nipple discharge, changes in the breast or nipple, or a lump in his breast, armpit, or chest wall, should bring these findings to the attention of his health care provider, and breast cancer should be considered in the differential diagnosis. Too often, both men and their health care providers ignore the signs that would immediately be explored and treated in a woman presenting with the same findings.

The second twist: Knowles had genetic testing and was found to carry a mutation in thegene called BRCA2. We all have two BRCA2 genes, but people born with a mutation in one of those genes are atincreased risk for several cancers, including breast, ovarian, pancreatic, and prostate cancer.Male breast cancer is seen at higher rates in men who carry a BRCA2 mutation, with a lifetime risk of seven percent as opposed to less than one percent in the general population. BRCA2 carriers also have a higher risk of developing multiple breast cancers.Consequently, Knowles, who currently has breast cancer in only one breast, plans to have both breasts removed to reduce his risk of developing a new breast cancer in the future.

Knowles also acknowledged that his children each have a 50% risk to carry the same BRCA2 mutation. The same is true for his siblings. When someone is found to carry a BRCA2 mutation, their family membersshould each be offered genetic counseling and testing by a trained professional.

The third twist:Knowles is of African American ancestry. Many patients and providers wrongly believe that BRCA mutations are only found in white Jewish women. While it is true that there are three BRCA mutations that are common in men and women of Jewish ancestry, there are thousands of other mutations in the BRCA genes that can be found in people ofallethnic backgrounds. We must begin to offer genetic counseling and testing consistently toallwomen and menwith significant personal or family histories of cancer.

So,who should be offered genetic counseling and testing? ALL men with breast cancer, period. Since Matthew Knowless story broke, Ive read multiple false accounts stating that men with breast cancer should be offered genetic testing onlyif they have a strong family history of cancer or are of Jewish ancestry. Wrong. ALL men with breast cancer are strong candidates for genetic counseling and testing. And importantly, most BRCA and other cancer gene mutations would be missed by the popular at-home direct-to-consumer genetic testing kits. If you need genetic testing for medical reasons,speak to a certified genetic counselor who can help you order a medical-grade test.

Angelina Jolie, Rome (Italy), October 7th, 2019 (photo by Marilla Sicilia/Archivio Marilla ... [+] Sicilia/Mondadori Portfolio via Getty Images)

When Angelina Jolie came out with her story in 2013, referrals to my clinic increased by 40% overnight and awareness of genetic testing and BRCA mutations changed forever. Matthew Knowles has just done the same for male breast cancer, BRCA2, and genetic testing of non-white women and men. His courageous decision to share something so personal will save lives.

See the original post here:
What Beyonces Dad And Angelina Jolie Have In Common - Forbes

Ancestry, the genealogy-focused genetics testing company, on Tuesday announced two new products that will provide consumers with health information based on DNA test resultsa move that places the company "in direct competition with 23andMe," according to STAT News.

What providers need to know about genetic testing and other new clinical innovations

The two AncestryHealth products AncestryHealth Core and AncestryHealth Pluswill look at 17 genes, including:

The products will also test for traits like lactose intolerance and caffeine metabolism. In addition, the tests will include clinical reports that consumers can give to their physicians.

However, the two products provide significantly different services. AncestryHealth Core will provide a one-time report with data based on consumer's DNA microarray. The product will cost consumers $49.

Meanwhile, AncestryHealth Plus will provide a more detailed report to consumers using next-generation DNA sequencing technology. While the AncestryHealth Plus product will initially focus on the 17 genes that the AncestryHealth Core product focuses on, it will technically sequence a consumer's "exome," or" all of the known genes that code for proteins in the body," according to STAT News. However, Ancestry will share only a limited portion of the resulting data with consumers. Consumers interested in the product will pay a one-time fee of $199, plus a $49 subscription fee every six months to receive quarterly reports with updates.

For the new products, Ancestry is teaming up with PWNHealth, a national network of physicians located in New York. For both products, consumers will order a DNA test from the company and complete a survey of their medical history, which is then reviewed by a PWNHealth physician for DNA test approval. The test results, when ready, are then reviewed by PWNHealth providers to ensure that consumers get the right educational materials along with the findingsfor instance, a consumer whose DNA test has potentially worrisome results would also receive an educational video about the condition.

Consumers will also receive video material on DNA testing before getting their results, and, after receiving their results, they will have access to both online resources and, if needed, genetic counselors also from PWNHealth.

According to Business Insider, 23andMe sells many of the same tests Ancestry plans to offer, including reports on carrier status for sickle cell anemia, cystic fibrosis, and Tay-Sachs Diseaseand more than 40 other conditionsfor about $200. 23andMe's tests can also tell consumers if they have an increased risk of Alzheimer's disease or Parkinson's disease, which Ancestry elected not to include.

However, since AncestryHealth will require physicians, rather than consumers, to order the DNA tests, AncestryHealth will operate under CMS' rules for physician-ordered diagnostic testing. In comparison, 23andMe applied for and received FDA approval so that it could make its DNA tests available directly to consumers without a prescription.

Margo Georgiadis, Ancestry's CEO, said the company elected to have doctors order the DNA tests "so that the consumer not only can find out a risk factor, but they can seamlessly take a lab report with clinically recommended guidelines into the doctor's office so that there's a clear next path for action."

Some experts expressed concern over how many genetic diseases the tests will provide information on, and said it's unclear how the patient counseling component of the program will work.

Eric Topol, director and founder of the Scripps Research Translational Institute, voiced concerns about the AncestryHealth Plus product in particular, noting that the American College of Medical Genetics advises providers to share information about harmful mutations in 58 genes with patients who have had their exomes sequenced. The AncestryHealth Plus product is "minimal," he said, adding that while it's "a step in the right direction," it's "not in keeping with consensus and practice in the medical community."

However, Catherine Ball, Ancestry's chief science officer, said the company decided to have its tests focus on only highly actionable diseases because it only wanted to include tests that can "improve outcomes for our customers and for their families."

Separately, David Agus, a professor at the University of Southern California, said, "What people don't get is that genetics are a tiny piece of the puzzle." He noted a study Ancestry and Google published in Genetics that found genes account for less than 10% in differences in people's lifespans.

Laura Hercher, director of research in human genetics at Sarah Lawrence College, said just 2% of patients who don't have a family history of disease would be expected to learn something medically useful from a DNA test. "Some people will get medically useful information from this," she said. But "[f]or most, the idea that DNA testing will help your doctor guide your health decisions is an overstatement" and "premature at best."

Robert Cook-Deegan, a professor at the University of Arizona who studies genome ethics and law, worried that many consumers may not understand their own DNA tests. "A lot of whether this is a good thing or a bad thing depends on the quality of their testing," he said. "It depends on the degree to which those physicians are really involved and the degree to which the genetic counseling is truly incorporated into the process."

Others expressed concerns of whether consumers will know they should be getting a different DNA test than the one they chose. For example, if patients wanted a BRCA1 or BRCA2 test because they had a family history of breast cancer, the AncestryHealth Core test will only tell them if their gene has a common "misspelling," meaning that several specific, cancer-causing mutations could be overlooked, STAT News reports. And while the AncestryHealth Plus test would be more likely spot such an issue if it's present, patients could be better off receiving a DNA test, such as those offered by Myriad Genetics, because those might be covered by insurance.

Robert Green, director of the Genomes2People research program at Brigham and Women's Hospital, said he's concerned patients may wrongly think they're at low risk of a disease because of an incomplete DNA test. "The risk, as with other the consumer genomics, is that patients will think this is somehow a comprehensive and encyclopedic investigation of your entire genomic health," he said. However, he added that "[d]iscovering some people who are carrying significant and actionable mutations is better than finding none of them" (Herper, STAT News, 10/15; Ramsey, Business Insider, 10/15; Brown, Bloomberg, 10/15).

Read this article:
Ancestry will offer health DNA tests, setting its sights on 23andMe - The Daily Briefing

Breast cancer survivor: I focused on God's promise, not the problem

Sherry Connelly has kept a positive outlook on as she takes her journey through the healing process from breast cancer.

Taylorsville native Sherry Connelly found out she had breast cancer on February 14, 2018.

Happy Valentines day to me, right? I was distraught. I was angry, Connelly admitted. She made sure to get a mammogram every year, but somehow it still slipped through the cracks.

I was like, How in the world did we miss this? She said she first discovered a lump in her breast, and had it checked by her primary care physician. She (Connellys doctor) said it was probably just a cyst, but to be on the safe side she had me go get an ultrasound and tests, she said.

The next doctor told Connelly she also needed a biopsy, which confirmed that she had breast cancer. It was hard, but I just had to look at the bright side; God had something for me to do, she said.

As she went through many chemotherapy and radiation treatments, she kept her mind on God. I just prayed and asked God to give me something to do so I wouldnt just focus on the problem. I wanted to focus on His promise, and not on the problem, she said.

During this time, Connelly played a part in a film called, Black Widows, produced by John Robinson. It was an amazing experience, she said. It kept my mind concentrated on something else, instead of wallowing and thinking, Oh no, am I going to make it?

Sherry Connelly displays her movie "Momma's Baby Boy" that she was working on when she was diagnosed with breast cancer.

Connelly also plans to act in two more films produced by Robinson. More information on the films can be found at http://www.bddentertainment.com.

Another factor that played into Connellys treatment was her support system. My mom shes 88-years-old she came to every treatment and every doctor's appointment. She was right there beside me, she said. My brother came when he could, too.

Connelly said the staff in the oncology department at Frye Regional Medical Center in Hickory was, just amazing.

If I came in and looked like I was not feeling the way I should be feeling, they would call the doctors and let them know," she said. "They would get me anything I needed, and it meant the world to me."

She remembers one nurse in particular Sherri Stone.

She has been amazing," Connelly said. "She would be off, and I could inbox her or call her and she would tell me what I needed to do.

When Connelly was in treatment, Stone was an infusion nurse in the oncology department, but would go above and beyond her job description to help patients like Connelly.

If I needed something, she (Stone) could just tell and she would make that call for me. She made sure that I got what I needed, Connelly said. I love her.

Today, Stone is an oncology nurse navigator and continues to support cancer patients at Frye. Connelly said without that support, battling cancer is much harder.

It means everything for you to have a support system, she said. Youre going to have those days where you just feel like giving up, throwing in the towel. I felt like that, but you have to keep fighting and push through.

People think that cancer is a death sentence, she continued. Its not now. There is so much technology out there to help, and you cant give up. Youve got to keep going.

Connelly is now in remission and plans to continue her acting career as long as she can.

Cancer navigators guide breast cancer patients through the early stages of diagnosis

Cancer navigator Crystal Deese at Catawba Valley Medical Center, discusses how she helps cancer patients navigate the numerous levels of patient care.

Throughout her nursing career, Crystal Deese has played many roles, but oncology has always had a special place in her heart.

Thats the whole reason I went into nursing was for oncology, Deese said. I was in high school when my grandmother was diagnosed with cancer. And I just remember her saying, I wont be here for you to help me, but you can help someone else.

For the last 20 years, Deese has worked with cancer patients in one way or another, whether that is at the start of the cancer journey, at the end of treatment or at the end of the battle with hospice care.

Now, Deese is the interim breast cancer navigator at Catawba Valley Medical Center.

The navigator, I guess you can say, is the middle person that connects them to the surgeon or the oncologist after the initial diagnosis, Deese said. Im the first person that makes contact with them. Me along with the radiologist, when we get the positive pathology report back, we bring them in and then point them to the surgeon.

Deese calls working with cancer patients a calling.

I have a strong faith, she said. ... Its not something that I would have ever chosen to do for money or write anything that way.

She feels the same way about her time working in hospice care.

It was a great honor to be invited into someones home and you be able to be there to take care of them, Deese said. It was a privilege more than anything. Then you get to see them where theyre happy and theyre comfortable, and where they want to be. Not in the hospital setting.

Working as a breast cancer navigator does have its challenges, especially since Deese doesnt have many answers for patients when theyre first diagnosed.

Deese and a radiologist are usually first to tell breast cancer patients that their biopsy came back positive for cancer. They cant really tell them exactly what type of treatment theyll receive or how long, but they can sometimes let the patient know that chemotherapy, radiation and maybe surgery are on the horizon.

Youre the first person to make contact with these ladies, and telling them whenever they get the diagnosis that yes, you have cancer, Deese said. But then we also like to say, yes, you have cancer, but now we know what were dealing with. And no, nobody has this as part of their plan, but now we can get you going in the right steps as to whats next.

When someone is diagnosed with breast cancer, Deese said, the reaction can vary. Sometimes the patient has many questions, and other times they are silent.

Cancer navigator Crystal Deese displays some of the cancer publications that she uses to help cancer patients with their journey.

The initial response, its so mixed, but most of the time its: Am I going to have to have chemotherapy? Will I have to have radiation? Or will I lose my breast altogether? What happens when you meet the surgeon? Deese said. Some have no questions. Some are just so overwhelmed. Theyre like Ill have to call you back, and then there are some that come in with questions.

If a patient has a financial hardship, Deese and the other cancer navigators can assist the patient in finding the right financial assistance programs as well as support groups, transportation services and more.

Deese says keeping up with your yearly breast exams is essential.

I dont think you can stress enough the importance of doing your screening mammograms, she said. Because I believe with the changes and the advances that weve made in treatment, its a very curable diagnosis, if we catch it early enough. So its the screening and prevention I think that can make the biggest difference.

Assessing your risk may help prevent breast cancer from affecting you and your family

By Melissa L. Teague, Frye Regional Medical Center

Most cancers start with abnormal cells growing out of control. Sometimes you will experience symptoms, but often you will not. Thats why cancer high-risk assessment programs are so important. Finding and treating cancer in its earlier stages is potentially lifesaving.

Frye Regionals clinic is staffed by a specially trained high-risk coordinator who helps assess your genetic risk for certain types of cancer including breast, ovarian, colon and uterine cancer. The coordinator gathers information about your background and family history and can help determine if further testing is necessary.

What is genetic testing?

Genes are found in chromosomes and are made up of DNA. We inherit genes from our parents. Our gene structure dictates how our body grows and regulates. When genes are normal, they work properly. When genes are abnormal or damaged, they can lead to disease. These are called gene mutations or changes. Some changes run in families (hereditary), and some happen by chance. A gene mutation can be the sole cause of disease. However, most diseases occur from a mixture of genetic and environmental factors.

Genetic testing looks at your genes to check for any mutations. The test is done with a sample of blood or saliva. There are several reasons why you might do genetic testing:

To diagnose a disease or a type of disease.

To determine the cause of a disease.

To determine treatment options for a disease.

To find your risk of getting a certain disease that possibly can be prevented.

To find your risk of passing a disease to your children.

How can a genetic counselor and/or high-risk coordinator help me know if I should have the screening?

Talk to your doctor if you think you are at risk for an inherited disease. They may refer you to a genetic counselor, who can review your family history and provide advice. They will ask you questions about your health and the health of your blood relatives. This information can calculate what your risk may be. It can help you decide whether you want to get testing. It also may determine if your insurance will pay for the testing.

How do you know who should be tested?

If one of your family members already has the disease, that person should get genetic testing first. This will show if their disease was passed down or occurred by chance. People from different ethnic groups are more at risk of certain diseases.

What does it mean if you are positive or negative?

A positive test result means that you have the gene change. This increases your risk of the disease. However, it does not guarantee that you will get the disease. It does mean you could pass the mutation to your children.

A negative test result means that you dont have the gene change. This may mean the disease doesnt run in your family or wasnt passed down to you. A negative result does not guarantee that you wont get the disease. It means that your risk of the disease is the same as it is for other people.

What about my children?

If your test is negative, you cannot pass a gene to your children; however, if you are positive, you could pass down the gene mutation to your children. It also means your daughters or sons may need closer surveillance for early detection.

Things to consider

Genetic testing has pros and cons. These can change depending on your situation. Keep in mind that genetic testing is voluntary. You should not feel forced to do it.

Some benefits of genetic testing include:

You may be less worried about developing a certain disease.

You may be motivated to change your lifestyle to reduce your risk.

You may be better prepared to move forward with family planning.

You may be able to get treatment to prevent the disease. This could include medication or surgery.

Your doctor will know how often to check for the disease.

Questions to ask your doctor

How do I know if I should see a genetic counselor?

If my genetic testing result is positive, what is my risk of getting the disease?

What can I do to prevent or treat the disease?

Should my genetic testing be done in a clinical setting or can I do it from home?

Breast cancer patients form special bond during treatment

photos Courtesy of Catawba Valley Medical Center

Courtesy of Catawba Valley Medical Center

When nurses noticed the uncanny similarities between breast cancer patients Kathy Rector and Cheryl Kiser, they decided to seat the women together during a chemotherapy treatment at Carolina Oncology Specialists in Hickory.

Rector and Kiser became fast friends, forming a bond over battling the potentially fatal disease and coining a name, Chemo Country Club, with the tagline now accepting short-term members only in honor of the place they met.

We were basically therapists for each other, Kiser said. We shared a wide range of emotions and strength in our determination to beat cancer. We inspired each other, lifted one another up, and found ways to belly-laugh through the process.

Both elementary school teaching assistants, Rector, 63, works with exceptional students at West Alexander Middle School and Kiser, 51, helps in kindergarten and first grade at Sherrills Ford Elementary, where she also drives a bus route.

The women synchronized treatment appointments and remained in touch through texts and calls along the way.

We found empathy, hope and companionship in the common ground of side effects hair loss, nausea, vomiting, nerve pain, and chemo brain, Rector said.

They also drew strength from their husbands, children and faith in God.

How they were diagnosed:

Notably, both women discovered suspicious lumps by self-exam despite having clear 3D mammograms within eight months before diagnosis.

Rector:My sister faced breast cancer two years ago, but we didnt have a family history of the disease before then. When I felt a lump about 2 inches in diameter in the center of my breast during vacation last September, I saw my gynecologist the following week and got the news a diagnosis of triple-negative T2 breast cancer with positive lymph nodes.

Kiser:My mother and grandmother both had breast cancer, so I took the BRCA genetic test to see if I was prone to the disease. Results showed no, but when I felt a lump, I made a beeline to Dr. Elizabeth Restino at Catawba Valley Family Medicine-Southeast Catawba, my primary care physician. She ordered a breast ultrasound and biopsy at Catawba Valley Imaging Center which confirmed the presence of T3 invasive ductal carcinoma, meaning cancer had spread to the tissue under my arm. A PET scan also revealed tumors on my ovaries.

Rector and Kiser both recall the quick transition of initial shock to fierce determination. After the sadness of delivering such emotional news to family and friends over the holidays, they faced the difficult process of telling faculty, parents and students at their schools, which triggered additional worry and a more public form of concern.

Rector continued working through treatments, wearing a mask to minimize germ exposure in the smaller setting of her classroom. But Kiser took a leave of absence given the extended population she came in contact with daily. From here, the battle ensued.

Rector:I had a breast lumpectomy in November, started chemo in December and then began 32 radiation sessions at Catawba Valley Health System Radiation Oncology. Two days after Christmas, my hair started coming out. The more I brushed, the more I cried. I tried wearing a wig, but it gave me such a headache, I decided just to wear hats. Late February, my first grandchild, Aubrey, was born when I was sick. I had to wait two long weeks before traveling to Ocean Isle and hold her in my arms.

Kiser:For me, processing my diagnosis was a God thing. He allowed me to absorb things one at a time. I didnt do research on my own. Instead, I protected my mind and trusted Dr. Orlowskis recommendations to first shrink the breast tumor with chemo before having surgery to remove that breast and my ovaries. As radiation began, Kathy and I had radiation mapping done to identify precise targets for the True Beam radiation system to prevent damage to surrounding healthy tissue. Kathy wanted to compare maps, so we laughed about where they marked an X on my treasure map, and that her map had a whole lot of hills!

Prayers and acts of kindness enveloped the newfound friends during the long and challenging months of their respective cancer treatments. From extended family to people in their church and school communities, both expressed deep gratitude for the uplifting support that saw them through.

Rector:Im extremely grateful for all the people who lifted me up in prayer and the churches that sent handcrafted prayer shawls, which I draped over me during treatments. I was also touched when West Alexander Middle School initiated a fundraiser and wore Team Rector T-shirts in the Cancer Relay for Life.

Kiser:I didnt think I was very vain. But when I lost my hair, I didnt want to leave my room. Austin, my oldest son, had an ongoing bet with his college roommate about who would first cut their hair. Guess what? Austin cut his hair and made a wig for me!

As the women reached key milestones and learned that treatments worked, they celebrated with each other and their whole care teams.

The pair has fond memories of the doctors and nurses who worked to save their lives:

Courtesy of Catawba Valley Medical Center: Kathy Rector (left) and her friend Cheryl Kiser celebrate the end of their chemotherapy treatment for breast cancer at Catawba Valley Medical Center. The two became friends while undergoing treatment.

Debbie, at Catawba Valley Health System Radiation Oncology, who inspired them with her personal story of survivorship; Dr. Reggie Sigmon, radiation oncologist and Len Hurst, medical physicist; Dr. Richard Orlowski, oncologist and Diane Fox, physician assistant, both at Carolina Oncology Specialists; and Wake Forest Baptist Health general surgeon Dr. Kenneth Parrish, general surgeon.

See the original post:
PINK: Stories and photos devoted to the warriors who fight breast cancer - Hickory Daily Record

Blind and partially sighted people no longer have to wait passively for a research breakthrough in hope of treatment options. In fact, people living with genetic eye conditions can now actively drive vision research forward by enrolling in a patient registry and getting their genes tested.

There are 2.2 billion people living with visual impairment globally. Some are living with inherited retinal diseases that are progressive and can lead to complete blindness. Up until recent years, blind and visually impaired people were told that no treatment is available. This is changing as genetic testing is paving the way for a surge of gene therapies.

My doctoral dissertation at the University of British Columbia was on drug therapy for retinitis pigmentosa. This progressive, blinding eye condition is the most common type of inherited retinal disease.

In people affected by retinitis pigmentosa, the light sensing cells in their retina photoreceptors die early. Unlike skin cells that regenerate, the body does not make more photoreceptors once they are damaged.

As a vision scientist affected by retinitis pigmentosa, I am passionate about finding the truth about the disease. Why do photoreceptors die? How can we stop it? How can science and medicine help?

When I was 12 years old, I realized while at summer camp that my night vision was disappearing. In the last two decades, I lost my peripheral vision, contrast sensitivity and depth perception.

I worked in Dr. Orson Moritzs lab at the UBC department of ophthalmology and visual sciences, which focuses on research using tadpoles that contain known human mutations for retinitis pigmentosa to understand the disease.

I made an alarming discovery in our animal model: knowing the genetic cause of retinitis pigmentosa is vital for treatment with one class of drugs histone deacetylase inhibitors. These determine how genes are switched on or off.

A similar study in mice showed that the same drug reacted differently to variations in a single mutant gene that also causes retinitis pigmentosa.

Treating retinitis pigmentosa is like extinguishing fire. To stop a fire, you need to know whether its water-based or grease-based. If you try to use water to stop a grease fire, the damage gets worse.

Blind and visually impaired people can advocate for eye health by enrolling in a patient registry. Participation in a registry benefits researchers by offering more information about the disease.

In Canada, individuals can self-refer to Fighting Blindness Canadas secure, clinical patient registry. This database is dedicated to connecting people living with retinal eye diseases to clinical trials and research.

When a gene therapy trial arises, researchers draw participants from this database. Since gene therapy aims to correct an underlying genetic mistake in DNA that causes disease, knowing the genetic cause of a disease is a criteria for most gene therapy trials.

Globally, other registries include My Retina Tracker in the United States, Target 5000 in Ireland, MyEyeSite in the United Kingdom, the Australian Inherited Retinal Disease Registry and Japan Eye Genetics Consortium. In New Zealand, Dr. Andrea Vincent has established the Genetic Eye Disease Investigation Unit. There is even a Blue Cone Monochromacy Patient Registry for one rare eye condition.

In the last two decades, the number of gene therapy trials has blossomed. Currently, 250 genes on inherited retinal diseases have been identified. In 2017, the first gene therapy for inherited retinal disease Luxturna was approved by the United States Federal Drug Administration.

To date, there are trials for: retinitis pigmentosa; Usher syndrome, a condition that involves hearing and vision loss; achromatopsia, a disease that causes colour blindness; X-linked retinoschisis, a dystrophy that causes splitting of the retina and affects mostly in males; and age-related macular degeneration, the third-largest cause of vision loss worldwide, caused by the interplay between genetics and environment.

Enrolment in a patient registry and genetic testing advance the design of gene therapy trials. This in turn benefits blind and visually impaired people.

Research advancement is a concerted effort across the globe blind and partially sighted people should know they have the power to push it forward.

[ Like what youve read? Want more? Sign up for The Conversations daily newsletter. ]

Go here to see the original:
The blind and visually impaired can help researchers by getting their genes tested - The Conversation CA

Stem cell therapy for animals has seen breakthroughs

Stem cell therapy is increasingly becoming a more mainstream form of medicine. Usually applied to humans, the use of this regenerative treatment is now also being extended to animals including cats and dogs. Regenerative medicine, particularly stem cell treatment has seen many advancements in recent years with some groundbreaking studies coming to light.

Taking the cells from bone marrow, umbilical cords, blood or fat, stem cells can grow to become any kind of cell and the treatment has seen many successes in animals. The regenerative therapy has been useful particularly for treatment of spinal cord and bone injuries as well as problems with tendons, ligaments and joints.

Expanded Potential Stem Cells (EPSCs) have been obtained from pig embryos for the first time. The cells offer groundbreaking potential for studying embryonic development and producing transnational research in genomics and regenerative medicine, biotechnology and agriculture.

The cells have been efficiently derived from pig preimplantation embryos and a new culture medium developed in Hong Kong and Cambridge enabled researchers from the FLI to establish permanent embryonic stem cell lines. The cells have been discovered in a collaboration between research groups from the Institute of Farm Animal Genetics at the Friedrich-Loeffler-Institut (FLI) in Mariensee, Germany, the Wellcome Trust Sanger Institute in Cambridge, UK and the University of Hong Kong, Li Ka Shing Faculty of Medicine, School of Biomedical Sciences.

Embryonic stem cells (ESC) are derived from the inner cells of very early embryos, the so-called blastocysts. Embryonic stem cells are all-rounders and can develop into various cell types of the body in the culture dish. This characteristic is called pluripotency. Previous attempts to establish pluripotent embryonic stem cell lines from farm animals such as pigs or cattle have resulted in cell lines that have not really fulfilled all properties of pluripotency and were therefore called ES-like.

Dr Monika Nowak-Imialek of the FLI said: Our porcine EPSCs isolated from pig embryos are the first well-characterized cell lines worldwide. EPSCs great potential to develop into any type of cell provides important implications for developmental biology, regenerative medicine, organ transplantation, disease modelling and screening for drugs.

The stem cells can renew themselves meaning they can be kept in culture indefinitely, and also show the typical morphology and gene expression patterns of embryonic stem cells. Somatic cells have a limited lifespan, so these new stem cells are much better suited for long selection processes. It has been shown that these porcine stem cell lines can easily be modified with new genome editing techniques such as CRISPR/Cas, which is particularly interesting for the generation of porcine disease models.

The EPSCs have a high capacity to develop not only into numerous cell types of the organism, but also into extraembryonic tissue, the trophoblasts, making them very unique and lending them their name. This capacity could prove valuable for the future promising organoid technology, where organ-like small cell aggregations are grown in 3D aggregates that can be used for research into early embryo development, various disease models and testing of new drugs in petri dishes. In addition, the authors were able to show that trophoblast stem cells can be generated from their porcine stem cells, offering a unique possibility to investigate functions or diseases of the placenta in vitro.

A major hurdle to using neural stem cells derived from genetically different donors to replace damaged or destroyed tissues, such as in a spinal cord injury, has been the persistent rejection of the introduced material (cells), necessitating the use of complex drugs and techniques to suppress the hosts immune response.

Earlier this year, an international team led by scientists at University of California San Diego School of Medicine successfully grafted induced pluripotent stem cell (iPSC)-derived neural precursor cells back into the spinal cords of genetically identical adult pigs with no immunosuppression efforts. The grafted cells survived long-term, displayed differentiated functionality and caused no tumours.

The researchers also demonstrated that the same cells showed similar long-term survival in adult pigs with different genetic backgrounds after only short course use of immunosuppressive treatment once injected into injured spinal cord.

Senior author of the paper Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine said: The promise of iPSCs is huge, but so too have been the challenges. In this study, weve demonstrated an alternate approach.

We took skin cells from an adult pig, an animal species with strong similarities to humans in spinal cord and central nervous system anatomy and function, reprogrammed them back to stem cells, then induced them to become neural precursor cells (NPCs), destined to become nerve cells. Because they are syngeneic genetically identical with the cell-graft recipient pig they are immunologically compatible. They grow and differentiate with no immunosuppression required.

Co-author Samuel Pfaff, PhD, professor and Howard Hughes Medical Institute Investigator at Salk Institute for Biological Studies, said: Using RNA sequencing and innovative bioinformatic methods to deconvolute the RNAs species-of-origin, the research team demonstrated that pig iPSC-derived neural precursors safely acquire the genetic characteristics of mature CNS tissue even after transplantation into rat brains.

NPCs were grafted into the spinal cords of syngeneic non-injured pigs with no immunosuppression finding that the cells survived and differentiated into neurons and supporting glial cells at all observed time points. The grafted neurons were detected functioning seven months after transplantation.

Then researchers grafted NPCs into genetically dissimilar pigs with chronic spinal cord injuries, followed by a transient four-week regimen of immunosuppression drugs again finding long-term cell survival and maturation.

Marsala continued: Our current experiments are focusing on generation and testing of clinical grade human iPSCs, which is the ultimate source of cells to be used in future clinical trials for treatment of spinal cord and central nervous system injuries in a syngeneic or allogeneic setting.

Because long-term post-grafting periods between one and two years are required to achieve a full grafted cells-induced treatment effect, the elimination of immunosuppressive treatment will substantially increase our chances in achieving more robust functional improvement in spinal trauma patients receiving iPSC-derived NPCs.

In our current clinical cell-replacement trials, immunosuppression is required to achieve the survival of allogeneic cell grafts. The elimination of immunosuppression requirement by using syngeneic cell grafts would represent a major step forward said co-author Joseph Ciacci, MD, a neurosurgeon at UC San Diego Health and professor of surgery at UC San Diego School of Medicine.

Other recent advancements include the advancement toward having a long-lasting repair caulk for blood vessels. A new method has been for generating endothelial cells, which make up the lining of blood vessels, from human induced pluripotent stem cells. When endothelial cells are surrounded by a supportive gel and implanted into mice with damaged blood vessels, they become part of the animals blood vessels, surviving for more than 10 months.

The research was carried out by stem cell researchers at Emory University School of Medicine and could form the basis of a treatment for peripheral artery disease, derived from a patients own cells.

Young-sup Yoon, MD, PhD, who led the team, said: We tried several different gels before finding the best one. This is the part that is my dream come true: the endothelial cells are really contributing to endogenous vessels.

When cells are implanted on their own, many of them die quickly, and the main therapeutic benefits are from growth factors they secrete. When these endothelial cells are delivered in a gel, they are protected. It takes several weeks for most of them to migrate to vessels and incorporate into them.

Other groups had done this type of thing before, but the main point is that all of the culture components we used would be compatible with clinical applications.

This research is particularly successful as previous attempts to achieve the same effect elsewhere had implanted cells lasting only a few days to weeks, using mostly adult stem cells, such as mesenchymal stem cells or endothelial progenitor cells. The scientists also designed a gel to mimic the supportive effects of the extracellular matrix. When encapsulated by the gel, cells could survive oxidative stress inflicted by hydrogen peroxide that killed unprotected cells. The gel is biodegradable, disappearing over the course of several weeks.

The scientists tested the effects of the encapsulated cells by injecting them into mice with hindlimb ischemia (restricted blood flow in the leg), a model of peripheral artery disease.

After 4 weeks, the density of blood vessels was highest in mice implanted with gel-encapsulated endothelial cells. The mice were nude, meaning genetically immunodeficient, facilitating acceptance of human cells.

The scientists found that implanted cells produce pro-angiogenic and vasculogenic growth factors. In addition, protection by the gel augmented and prolonged the cells ability to contribute directly to blood vessels. To visualise the implanted cells, they were labelled beforehand with a red dye, while functioning blood vessels were labelled by infusing a green dye into living animals. Implanted cells incorporated into vessels, with the highest degree of incorporation occurring at 10 months.

Visit link:
Stem cell therapy is for animals too - SciTech Europa

Hematopoietic stem cell transplantation (HSCT), popularly known as bone marrow transplantation (BMT), is a curative modality for a number of benign and malignant blood disorders, said Dr. Murali Krishna Voonna, surgical oncologist and managing director of Mahatma Gandhi Cancer Hospital and Research Institute.

Speaking at an awareness programme on stem cell donation organised here by the hospital, in association with Datri Blood Stem Cell Donor Registry, he said hematopoietic stem cells are immature cells that can develop into all types of blood cellswhite blood cells, red blood cells, and platelets. They are found in the peripheral blood and bone marrow.

A sizeable population are diagnosed to have benign diseases such as thalassemia major, sickle cell anaemia and aplastic anaemia, and the HSCT is among the efficient curative measures. Acute leukaemia and other blood cancers also need this procedure, he said.

Highlighting that stem cell donation and a registry are vital, Dr. Muralikrishna explained for a successful hematopoietic stem cell transplant, the patients genetic typing (HLA typing) needs a close match with that of the donor. Every patient has 25% chance of finding a match within the family, he said.

Dr. Muralikrishna stated that in such cases, finding a donor is a pressing need. There are over 80 donor registries and more than 30 million registered donors across the globe, with a very few Indians being a part of it. This reduces the chances of finding a possible match for patients of Indian origin. Patients are more likely to find a possible match within their ethnicity, which means people sharing the same cultural linguistic and biological traits, he explained.

The problem can be solved if the donors enroll themselves with a registry which will store the stem cell details and the details. Pledging to donate stem cells is easy like swabbing the inner-cheek. The donors are contacted if patients have HLA matching, he said, adding that the stem cell donation was carried out only when a match was found for a patient, not when one pledge to donate.

A blood stem cell collection centre was inaugurated at the hospitals premises on the occasion. Earlier, to avail of such service and for HLA-typing, one has travel to Hyderabad and Chennai, Dr. Muralikrishna said.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading our articles without intrusion from advertisements.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

See original here:
More awareness needed on stem cell donation: expert - The Hindu

Bhubaneswar: The advanced treatment of using stem cells for treating Autism and other neurological ailments have come as a ray of hope for the people living with some of these ailments. Medical experts working in the sector claim that the use of the technology improved the lives of many.

According to experts who practice stem cell therapy, the results have been overwhelming. Many of the patients have either been able to fight a deadly disease with the help of stem cells while many have been able to improve their quality of lives by using it. However, the technology is still not used widely in state hospitals.

Medical experts claim that stem cells could be used to treat neurological disorders like Autism, cerebral palsy, mental retardation, brain stroke, muscular dystrophy, spinal cord injury, head injury, cerebellar ataxia, dementia, motor neurone disease, multiple sclerosis while it has also been used to treat cancers like blood cancer with the help of bone marrow transplant when assisted by stem cell therapy.

However, treatment of Autism with stem cells is a new developing sector where visible changes are said to have been reported among children treated with this technology. However, the advanced technology which is now confined to only private sector is a bit expensive.

Autistic kids are usually treated with drugs for symptomatic relief, special education, occupational speech and behavioural therapies. In Autism, despite the best available medical and rehabilitative treatments satisfactory relief is still a far cry, said Dr Nandini Gokulchandran, Head Medical Services, NeuroGen Brain and Spine Institute, Mumbai.

Dr Gokulchandran claims that she has treated many cases of Autism in kids with stem cells which helped in overcoming their limited abilities. Under the treatment regime, an insertion procedure is undertaken followed by training to improve the skills and abilities of autistic kids.

Another neurologist, Dr Richa Bansod said that in India it has been reported that 1 in every 250 children have Autism and this number in increasing with better recognition and awareness of the condition. On the other hand, stem cells are now been used to fight deadly diseases.

Dr Joydeep Chakaborty, an oncologist and stem cell expert from HCG Cancer Hospital, Kolkata said, Stem cells and bone marrow transplants are now being used to cure blood cancer in many cases. It is also widely used to treat blood disorders like Thalassemia, Sickle Cell Anaemia and others.

Visit link:
Stem cells treatment gives hope in fighting Autism, blood disorders - OrissaPOST

For anyone who has had hip replacement surgery, Im sure they will agree that it is better to get hit by a bus than to undergo another one. Last year after several years of suffering, I decided to take the leap and go for the hip replacement that my specialist recommended. I was told that it was a common surgery and that it was the best solution for me. Between us; it was probably the most painful thing I have ever gone through. So much so, that at the time, I just wanted to die. Not only did the pain persist for several weeks after the operation, but I was on painkillers for days, which eventually added to my suffering. I had to use a walker for the first 2 weeks and then depended on a cane for over 2 months before I could walk on my own.

My entire demeanor changed, as well as the way I dealt with what once were minor things in life. I feared slipping in the shower, going down the stairs or walking my dogs. No one had prepared me for this. Ive had my share of surgeries including a double mastectomy when I was diagnosed with breast cancer but pain wise; this one was by far the worse. I was hoping after a very long recovery that I would never have to face this situation again. Unfortunately, a year later, I am starting to feel pain on the other side and dread the re-experience of my nightmare.

Although, I heard about Stem Cell, I did not know much about it. So I started to investigate for myself, speak to people, enquire about the procedure and look for a doctor in my area who specialized in Stem Cell. I was willing to do just about anything before considering another hip replacement. After extensive research, I came across Dr. Raj, a Double-Board Certified Orthopedic doctor in Beverly Hills, CA. Going to his website; I learned that he has been in private practice for 10 years. He has been named as one of Americas Top Orthopedists, been featured on the Best of LA and has received numerous other accolades and awards as one of the Top Orthopedic doctors. Providing the ultimate in state-of-the-art orthopedic care, Dr. Rajs practice is always on the cutting-edge of surgical and nonsurgical technologies, such as PRP (Platelet Rich Plasma) injections, stem cell injections for tendinitis and arthritis, minimally invasive surgery and more.

He is Board Certified as a Medical Legal Specialist in America, as well as, Canada and Dubai (Trial, Testimony, Deposition, IME) with a Subspecialty in Hip and Knee Surgery in Los Angeles, including Sports Surgeries.

He is also an Undergraduate from Dalhousie University in Halifax and Canada. He pursued his medical education at Memorial University PGME, before doing his internship and residency in the Department of Orthopedic Surgery. Now that I had found Dr. Raj, all I needed was to get myself educated. So lets start by what are stem cells? This is what I read: Mesenchymal stem cells (MSCs), commonly called stem cells, are precursor cells that havent decided yet what they are going to be in the body. They can differentiate into multiple forms including bone, cartilage, fat and other connective tissues. They play a significant role in the reparative processes throughout the human body.

Where do we find stem cells?

They may be harnessed from fat tissue, bone marrow, synovial tissue or umbilical cord tissue. While stem cell therapy is a promising technology, there is much we are still learning about the causes and pathways that lead to symptomatic osteoarthritis. We have not optimized the factors found in stem cell therapies. To be sure, only the good cells and growth factors are injected into a specific joint. And that is why further research is necessary before being approved by the FDA.

My next move would be to consult with Dr. Raj who would tell me the medical truth, beginning with this question:

What is the current state of Stem Cells and its success rate?

It's relatively new. It's been popular for about 20 years, internationally. In areas like Germany and Korea, it was utilized a lot more. It became popular here when athletes like Kobe Bryant started going to Germany for modified versions of PRP, which led on to regenerative technologies. We have a stigma correlating stem cells with abortions and issues like that. This in itself is completely different. We are not utilizing amniotic stem cells or placenta stem cells. We're utilizing your own stem cells. For issues such as a hip replacement, the most powerful stem cells are the ones in your body. Bone marrow stem cells work well on joints. Joints have zero blood supply. So, if God or the higher power created us where we had blood supply going through our joints, like a cut in our skin - we would constantly replenish or repair. A break in our bone would repair. If you get stem cells and you're in decent enough shape, you will heal no matter what because these stem cells will deposit. Will you heal straight? Probably not - that's where we come into play.

The reason why joints; hips, knees and shoulders degenerate is because there is no blood supply. So, if you have a cut or a loss of cartilage, it stays like that and accumulates overtime. The only way you can control it is externally. You get stronger, you lose weight and you increase your range of motion. But you can't control anything internally.

So regenerative technology is basically utilizing these cells to regenerate cartilage and repair. These are the same cells that flow through our body - and upon signal of an injury will heal skin to skin, bone to bone, tendon to tendon, muscle to muscle. Our joints are just an alcove of joint fluid and no blood supply. The whole concept is - throughout the years, we did steroid injections - they're like band aids. Basically they mask pain. What does masking pain do? It propagates injury. Because we put the band aid on, we don't feel it and we do more. We take this little cut or loss of cartilage and we make it even more over time.

Why is it that specialists do not recommend seeing a surgeon at a certain stage?

There are a lot of people who think one way and everyone is entitled to their own opinions. You can't change opinions.

Are people afraid of stem cells?

Some people are afraid because of stem cells causing cancer. But that's embryonic stem cells.

What is the process?

Bone marrow stem cells are the best because there is a higher chance of live stem cells. Less manipulation, meaning that - in a Mayo Clinic study 4 or 5 years ago, which has a two year follow through on people who are ready to get replacements for joint or knee - they had an 80% success rate where they didn't need it. I do replacements and I do stem cells.

How do you determine what's better for the patient?

My knowledge and years of experience. Also, my knowledge with fitness and being athletic myself. Understanding at a certain point, someone is mechanically compromised. Bone on bone is a term that's been used for years. There are a lot of people who think they are 'bone on bone." Coming from Canada, the US is notorious for doing unnecessary surgeries and replacements. It's the highest rate of replacements in the world. I do not like the term 'bone on bone' because a surgeon will look at an x-ray and say you're bone on bone because that's all they do: replacements. They become a 7-11 or 99 Cents store, lining up 21 people a day. That's not the right way to do things. You don't want to be one of those 21 people getting a replacement because you're not getting that surgeon's full attention. The reality is - you have a PA or an old plastic surgeon who's doing most of your surgery and there is more likelihood of issues. Amongst every specialty there is a lot of ignorance. The whole concept is - you preserve what you have for as long as you can. You have beauty on the outside; you need beauty on the inside too. What's beauty on the inside? Feeling good, you're less inflamed and your joints are healthy.

How does it work with a stem cell procedure?

I extract bone marrow from your pelvis. Take approximately 6 ccs. Under slight sedation, it takes about 5 minutes to take it. Then we separate it via an FDA approved technique. Per FDA, we cannot add anything to it, nor would I want to. We cannot harvest it because the longer it's outside of the body, the better it is. Basically, we then inject those pure cells right away into the joint. It's a four month process for an 80% of regeneration. So, it's not just reduction of inflammation, it's regeneration. It will be a year for a 100% effect. I've had probably about 20% of patients who have taken 6 months+. I've had over a 95% success rate with this technology.

Are you one of the only doctors doing this in LA?

I'm one of them. There are some family and pain management doctors who are doing it. I'm the only Orthopedic surgeon doing it. I'm sure different practitioners are starting to.

Dr. Raj and patient Paula Abdul

How often do you do the stem cell procedure?

You do it one time. It's a powerful injection and there are people Ihave 6 years out who are doing well.

Does it hurt after the fact?

No, not at all. You can walk and move. For example, with your hip - I would combine it with physical therapy to increase your range of motion. Once you have the anti-inflammatory effect, you have to take advantage of it. If you don't increase your range of motion - what happens is - you're walking on one nail vs. 100 nails. You want to dissipate the force over a greater area so that there's a higher chance of external success. Then you strengthen the muscles.

Are there people who are not good candidates for it?

Yes, when it's too far gone. Like I said, people are told they're bone on bone when they're not. They show you different views. It's a marketing gimmick. That person is lined up and ready to sell. Age is relative. There's physiologic age. It really depends on the person. Hypothetically, if you're an inflamed mess, a drinker and abusive to your body, then nothing is going to work. If you take care of yourself and you're motivated with the right protoplasm, then it's going to work.

What about the skeptics or the ones who think it's bad for you?

Don't get me wrong; amniotic stem cells are good for certain situations. Embryonic is bad. It means that it's too far gone. You want live stem cells in an area that does not have blood supply. The data is out there. How can you argue against a Mayo Clinic study with an 80% success rate? How can you argue against the hospitals for special surgery in New York that's doing it, or the Steadman Hawkins Clinic, I'm doing it. Top facilities in the world are doing it and a number of top athletes who are getting it done with success rates. Who's ignorant? Is it that one surgeon or everyone else?

Does insurance cover it?

No, not yet. Insurances are very backwards in terms of their understanding. They would rather cover a replacement.

Is it expensive?

If you break it down par and par and avoid a replacement, not really. On average, you're talking about $7,000, versus hospital, surgeon, facility fees+++,which can be about $25,000.

You're very progressive.

There are a lot of things that I do to try and reduce pain significantly.When I use screws, I use screws that are made out of calcium so they dissolve in your body. Some of my colleagues use tourniquet, I don't use one. I control bleeding and do it in less than an hour. The whole concept is, you don't have atourniquetsqueezing your leg and toxins causing significant pain.

And there you have it. Everything is a risk in life, we do not know if we will wake up tomorrow or if you will get hit by a car and so on so why not try this procedure. I believe that I am lucky enough to have met Dr. Raj. I have taken the decision to undergo the stem cells therapy FDA approved or not, anything before going under the knife one more time. Stay tuned, I will give you a report on the progress.

Read the original:
Dr. Raj & Stem Cell Therapy Innovation - LATF USA

The Testosterone Replacement Therapy Market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align Testosterone Replacement Therapy market strategies according to the current and future marketThe Testosterone Replacement Therapy Market report covers the Global market and regional market analysis. The Testosterone Replacement Therapy industry report examines, keep records and presents the worldwide market size of the important players in each region around the globe. Also, the report offers information of the leading market players in the Testosterone Replacement Therapy market.

AccessGlobal Testosterone Replacement Therapy Market Research ReportDetails at: athttps://www.pioneerreports.com/report/301292

About Testosterone Replacement Therapy Industry

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.

The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.

The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.

Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.

North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.

North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%.

Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new GIR (Global Info Research) study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The overviews, SWOT analysis and strategies of each vendor in the Testosterone Replacement Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Testosterone Replacement Therapy market are:

Request for Sample Copy of this Testosterone Replacement Therapy Market Report athttps://www.pioneerreports.com/request-sample/301292

Important application areas of Testosterone Replacement Therapy are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Testosterone Replacement Therapy market. The market study on Global Testosterone Replacement Therapy Market 2018 report studies present as well as future aspects of the Testosterone Replacement Therapy Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Application of Testosterone Replacement Therapy Market are:

Product Segment Analysis of the Testosterone Replacement Therapy Market is:

Look into Table of Content of Testosterone Replacement Therapy Market Report at https://www.pioneerreports.com/TOC/301292

Regions Covered in Testosterone Replacement Therapy Market are:-

Inquire for further detailed information of Testosterone Replacement Therapy Market Report at:https://www.pioneerreports.com/pre-order/301292

The Testosterone Replacement Therapy Market Report is Prepared with the Main Agenda to Cover the following points:

Report Price: USD 3480

No of Pages in Testosterone Replacement Therapy Market:120

Analysis & Forecast Time Period: 2015-2024

Purchase Reportathttps://www.pioneerreports.com/checkout/301292

Follow this link:
Analysis of Testosterone Replacement Therapy Market Based On Market Capacity, Technological Advancement, Production and Growth Rate 2024 - eBurban

Eighteen-year-old Aisha Choudhary was just like any other adolescent eyes filled with dreams and a heart brimming with energy. The only difference was she was battling a rare genetic disease, Severe Combined Immune Deficiency (SCID). Diagnosed when she was six months old and undergoing medical treatment for years, she was iron-willed in playing the cards she was dealt.

Since one of the most effective cures for SCID is a stem cell transplant (grafting of the parent cells from which all blood cells develop), Aishas parents, Niren and Aditi, decided to opt for that treatment mode. But their cells were not a complete match with their daughters, and they had to look at external donors. However, due to a low number of voluntary, registered stem cell donors, Aisha could not get a compatible donor whose genetic markers were a close enough match to hers. With no other alternative treatment available, Aisha had a bone marrow transplant. But, it came with a side-effect that cost her life Pulmonary Fibrosis, a disease known to damage the lung tissues.

Aishas Choudhary's role has been played by Zaira Wasim in The Sky is Pink.

Aishas journey has been captured in The Sky is Pink, a recent Bollywood movie starring Priyanka Chopra, Farhan Akhtar, Zaira Wasim, and Rohit Saraf.

The 18-year-olds life story is mirrored in the experiences of many who await stem cell donation as treatment for blood-related illnesses likeleukemia, lymphoma, and sickle cell anemia every year. With very few individuals signing up as donors and the probability of finding a match being a dismal 0.0008 percent in India (against a lean 16 percent abroad), fatalities are mounting year on year.

However, in recent times, there has been one small break in the clouds a number of youngsters, non-governmental organisations, and medical professionals have come forward and are working to spread awareness about stem cell donation and motivate a larger number of people to register as donors.

The stem cells in a human body mainly comprise red blood cells, platelets, and white blood cells. These are found in the umbilical cord of newborns and in the peripheral or circulating blood and bone marrow.

A stem cell donation is as simple and painless as a blood donation.

Certain diseases like blood cancer and leukemia tend to destroy the bone marrow or affect its functioning.For these, treatments like chemotherapy and radiotherapy are tried initially. However, in some cases, they do not prove effective for a cure. The only recourse then is replacing the patients stem cells with those of a healthy person.

One of the main criteria for a successful transplant is a good match between the stem cells of the donor and those of the patient. Therefore, a donor registry will administer a cheek swab test (tissue samples extracted from the cheek) on all potential donors to match cell characteristics. This procedure of pairing generic markers is called Human Leukocyte Antigen (HLA) in medical terms.

A cheek swab test in progress.

Each potential donors tissue is entered in the registry and given an identification number after the test is done. If the registry finds a match at any point in time, the donor is contacted to initiate the transplant.

There are many organisations today that are leading the charge in saving the lives of people suffering from serious blood disorders like cancer, thalassemia, and anaemia.

For instance, Datri, an Ahmedabad-based NGO, is working to create a wide and diverse database of potential stem cell donors by organising donation drives. Founded in 2009 by two doctors and an engineer, the organisation focuses on conducting awareness campaigns and helping individuals sign up on its registry as a committed and voluntary benefactor.

The team of the NGO Datri.

The idea for Datri was initially born in the minds of doctors Nezih Cereb and Soo Young Yang, who run a laboratory, Histogenetics, for determining tissue matches between patients and donors. Since pairing tissue types is imperative for any stem cell transplant, and confronting a severe shortage of donors, the doctor duo would run from pillar to post to meet hospitals requirements. Working with a number of the hospitals in India, they realised just how acute the shortfall was in people willing to donate stem cells. They recognised the immediate need to create a donor registry here.

Soon after, Raghu Rajagopal, an engineer from BITS Pilani and Director of ready-to-eat venture Millets and More, connected with them and they decided to start Datri.

Today, the functioning of the registry, its maintenance, and even the substantial costs involved in conducting the HLA matching are taken care of by the lab. In the last 10 years, Datri has gotten over four lakh people to register as donors and has saved around 600 lives through successful transplantation.

Every day, about 40 people are diagnosed with blood disorders in India. Though these can be cured through a stem cell transplant from a genetically matched donor, there is only a 25 percent chance of finding a match from within the family. Others have no option but to rely on unrelated donors. But the chances of getting a match is anywhere between one in 10,000 and one in two million. There is an urgent need to rope in as many potential donors as possible, which is precisely what Datri is trying to do, Raghu explains.

Another organisation that is dedicated to fighting blood disorders with stem cell treatment is DKMS-BMST. It was formed through a joint venture between two renowned NGOs DKMS, which is one of the largest international blood stem cell donor centres globally, and the Bangalore Medical Services Trust (BMST).

The team of DKMS-BMST.

DKMS was founded in Germany in 1991 by businessman Dr Peter Harf, after he lost his wife to leukemia. BMST was born in 1984 from the vision of Dr Latha Jagannathan, a medical director and managing trustee. Since both organisations had a common goal to find a matching donor for every patient with a blood disorder, they decided to come together to achieve it.

A group of youngsters registering to be stem cell donors.

So far, more than 37,000 people in India have registered as potential donors after attending DKMS-BMSTs donor drives.

In highly populous countries like India, thousands of people are in need of stem cell transplants every year to survive. Though donating stem cells is a painless and non-invasive process, it remains a lesser-known medical concept in India, with only 3.6 lakh people willing to play a part in it. Besides, the chances of stem cells of people of the same ethnicity matching are higher than those of individuals from different ethnic backgrounds. But, it is due to sheer lack of awareness that India lags severely in stem cell donations, say experts.

Students taking a cheek swab test at one of the colleges in Bengaluru.

Dr Govind Eriat, a reputed hematologist and bone marrow transplant specialist, says,

With a major hurdle to stem cell donation in India proving to be the myths surrounding the subject, the youth are coming forward to deconstruct common misconceptions.

For instance, 21-year-old Tejaswini Patel, a student of Information Science at New Horizon College of Engineering, Bengaluru, has been busting the false ideas on stem cell donation, starting among her family and friends. She says,

She adds, with a notable sense of pride, In the last two years alone, around 400 students from my college have registered themselves as donors.

(Edited by Athirupa Geetha Manichandar)

See the article here:
How Young India is fuelling the future of stem cell therapy and signing up to save lives - YourStory

Stories of using the little blue pill for bone marrow transplants, how pregnancy stress is related to the baby's sex, and a vaccine for breast cancer proliferated on the Internet this week. Here's why you didn't read about them on Medscape.

Researchers at the University of California, Santa Cruz, seem to think Viagra has more to offer in medicine. In a recent study of mice, they tested whether the vasodilator couldspeed up the migration of hematopoietic stem cells and progenitor stem cells from the bone to the blood, where the cells could be harvested noninvasively.

The standard protocol for preparing bone marrow donors for the harvesting procedure, a 5-day regimen of granulocyte-colony stimulating factor (G-CSF),is "complex, costly, unsuccessful in a significant proportion of donors," the study authors write, and typically results in fatigue, nausea, and bone pain. Using a two-drug strategy, oral Viagra and a single injection of the CXCR4 antagonist AMD3100 (plerixafor), elicited the same mobilization of stem cells in 2 hours.

We didn't cover the study because it's still too early to say whether this strategy might be effective in people. After this mouse study, the next step is testing the approach in larger animals before human clinical trials.

A study of 187 healthy pregnant women age 18 to 45 years suggests that preterm mental and physical stress may be related to the baby's sex and increase the risk for preterm birth. In the study, 16% of women were physically stressed, as measured by higher blood pressure and calorie intake; and 17% were mentally stressed with high levels of depressionand anxiety; 66% of the women were in the healthy (nonstressed) group.

Women who were stressed during pregnancy were more likely to give birth to a girl. Typically, 105 males are born for every 100 females, but the study authors found that the male-to-female ratio decreased to 2:3 in psychologically stressed patients and 4:9 in physically stressed patients. Physically stressed mothers also gave birth an average of 1.5 weeks earlier than mothers in the healthy group, with 22% giving birth preterm compared with 5% in the healthy group.

The study authors say the findings demonstrate the importance of maternal mental health. Medscape has covered the consequences of maternal stress extensively, including preterm birth, neurobehavioral risks, and potential links to hyperactivity during the offspring's teen years. However, the sample size in this study was small: the mentally and physically stressed groups combined only included about 60 women. That's not sufficient to inform clinical practice in counseling women who want to get pregnant about how stress may affect the sex of their baby, so we didn't cover it.

News spread this week that Floridian Lee Mercker became the first woman to "beat" breast cancer with the help of a new vaccine. The vaccine, which stimulates the immune system to fight off early-stage breast cancer, was developed and administered by researchers at the Mayo Clinic in Jacksonville, Florida. The vaccine is currently in an early trial.

Reports of Mercker's success raise hopes, but she's reportedly the first participant in the trial. The news report also says she underwent a double mastectomy after her diagnosis in March, so it's unclear what evidence of the vaccine's efficacy the researchers measured. Before this experimental vaccine is relevant to Medscape readers, we need to see additional detailed data from more patients in the clinical trial published in a peer-reviewed journal.

Follow Medscape onFacebook,Twitter,Instagram, andYouTube

See original here:
The Week That Wasn't: Viagra BMTs, Pregnancy Stress, Breast Cancer Vaccine - Medscape